US20160256399A1 - Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole - Google Patents

Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole Download PDF

Info

Publication number
US20160256399A1
US20160256399A1 US15/030,302 US201415030302A US2016256399A1 US 20160256399 A1 US20160256399 A1 US 20160256399A1 US 201415030302 A US201415030302 A US 201415030302A US 2016256399 A1 US2016256399 A1 US 2016256399A1
Authority
US
United States
Prior art keywords
enteric
monolithic
capsule
active pharmaceutical
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/030,302
Inventor
Chang Q. Lee
Hassan Benameur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capsugel Belgium NV
Original Assignee
Capsugel Belgium NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capsugel Belgium NV filed Critical Capsugel Belgium NV
Priority to US15/030,302 priority Critical patent/US20160256399A1/en
Assigned to CAPSUGEL BELGIUM NV reassignment CAPSUGEL BELGIUM NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, CHANG
Assigned to Capsugel France SAS reassignment Capsugel France SAS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BENAMEUR, HASSAN
Assigned to CAPSUGEL BELGIUM NV reassignment CAPSUGEL BELGIUM NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Capsugel France SAS
Publication of US20160256399A1 publication Critical patent/US20160256399A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Definitions

  • the present disclosure relates to delivery systems and methods for increasing the bioavailability of active ingredients by oral monolithic enteric capsule administration to humans, particularly the administration of acid sensitive active ingredients such as omeprazole, esomeprazole, and other proton pump inhibitors, methods to deliver active pharmaceutical ingredients to humans or animals via hard capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.
  • Multiparticulate dosage forms with multiple release sites for active pharmaceutical ingredients, are expected to provide faster release rate profiles in blood than monolithic dosage forms such as capsules.
  • Residence time in the stomach strongly depends on the composition of the dosage form and the presence of food components, and multiparticulate dosage forms are expected to be emptied from the stomach quickly, on a similar time scale as solutions, i.e., within 10 to 60 minutes in a fasted state, or within 1-2 hours under a fed state.
  • Gastric emptying of a monolithic solid dosage form is delayed under a fed state, with a range of 4-7 hours depending on the caloric content of the meal. Gastric emptying time is shorter for multiparticulate dosage forms than for monolithic solid dosage forms, leading to correspondingly delayed pK values in blood for a monolithic dosage form.
  • Capsules are monolithic dosage forms widely used in the pharmaceutical field for oral administration to humans and animals of, e.g., various active ingredients, including pharmaceuticals, veterinary products, and food and dietary supplements. Advantages of capsules over other conventional dosage forms (such as tablets or liquids) may include better patient compliance, greater flexibility in dosage form design, taste masking, and less expensive manufacturing processes.
  • Capsules normally consist of a shell filled with one or more specific substances.
  • the shell itself may be a soft or a hard capsule shell.
  • Hard capsule shells are generally manufactured using dip molding processes, which can be distinguished into two alternative procedures.
  • capsules are prepared by dipping stainless-steel mold pins into a solution of polymer, optionally containing one or more gelling agents (e.g. carrageenans) and co-gelling agents (e.g. inorganic cations).
  • gelling agents e.g. carrageenans
  • co-gelling agents e.g. inorganic cations
  • thermogellation or thermogelling dip molding. See, e.g., EP 0401832, U.S. Pat. Nos. 3,493,407, 4,001,211, and 3,617,588, GB 1310697, and WO 2008/050209.
  • the aforementioned manufacturing processes involve the use of solutions of the different ingredients that are needed for the making the telescoping fit hard capsule shells.
  • Hard capsules may be filled with active ingredients via procedures known in the art. Typically, active ingredients are combined with various compatible excipients for ease of fill. The resulting fill may be a dry powder, a granulation, pellets, lipid pellets, a suspension, or a liquid. Additionally, stable, filled hard capsules have advantages over other dosage delivery forms such as liquids and solid tablets. Certain active ingredients may be difficult to formulate into dry granules, or may be otherwise incompatible with the tableting process. Another consideration is improved patient compliance for taste-masking and ease of swallowing, i.e., capsules being preferred by consumers over tablets.
  • Acid labile or acid sensitive active ingredients may require particular formulation steps to prevent active ingredient degradation and/or irritation of the stomach mucosa.
  • formulation steps include enteric coating, either of multiparticulates or granules, or of tablets formed from direct compaction and/or granulation of the active ingredients. Additional processing steps (such as granulation, coating, and/or tableting) add manufacturing complexity and resultant cost to pharmaceutical dosage forms. Other disadvantages include undesirable interaction with the enteric coating itself.
  • methacrylic acid copolymer a common enteric coating
  • pH neutralizing agent such as high levels of sodium bicarbonate, see, e.g., ZEGERID® (omeprazole product from Santarus). While such a formulation avoids the need for a coating step, these buffer-containing dosage forms have a high sodium content (inadvisable for patients on sodium restricted diets) and the need for a large amount of neutralizing agent results in a high formulation weight requiring a large capsule size, at least capsule size #0.
  • hard capsules may be coated in order to change the release characteristics of the capsule, such coatings require additional processing steps and are only able to be completed after active ingredient filling of a hard capsule.
  • the amount and the character of the coating must be adjusted by the end user for each formulation so that the desired characteristics are obtained.
  • Proton pump inhibitors are acid labile and may be the cause of gastric discomfort, and include compounds such as dexlanzoprazole, esomeprazole, ilaprazole, leminoprazole, lanzoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole and pharmaceutically acceptable salts, derivatives and enantiomers thereof are known.
  • Proton pump inhibitors are prescribed for the treatment of gastric-acid related diseases such as reflux esophagitis, gastric and duodenal ulcers, Zollinger-Ellison syndrome, and treatment of H. pylori infections.
  • Various proton pump inhibitor compounds are known and sold commercially. The use of such compounds in enteric coated pellet form has been disclosed, for example in U.S. Pat. No. 5,877,192 incorporated in its entirety herein.
  • Esomeprazole also known as perprazole, omeprazole S-form, and ( ⁇ )-omeprazole compositions are also commercially available, for example, sold under the trademark NEXIUM® (Astra Zeneca) in 20 mg and 40 mg doses, in tablet and capsule forms.
  • Esomeprazole (as the magnesium trihydrate, C 34 H 36 MgN 6 O 6 S 2 .3H 2 O) has a molecular weight of 767.17 g/mol and is slightly soluble in water (1.5 mg/ml in water at 25° C.), soluble in methane and insoluble in heptane. Esomeprazole degrades in acid conditions but is stable at pH 6.8.
  • Typical pharmaceutically effective amounts of esomeprazole for administration to humans range from about 5 mg to about 80 mg, administered once or twice daily.
  • FIG. 1 shows the mean plasma concentrations for 14 patients versus time for the monolithic esomeprazole enteric capsules without enteric coating (fed and fasted) according to Examples 6 and 7 and for the commercial delayed release capsule product with enteric coated pellets.
  • FIG. 2 is a stick plot comparing the C max (fasted) for the monolithic esomeprazole enteric capsule without enteric coating to the commercial delayed release capsule product with enteric coated pellets for each patient.
  • FIG. 3 is a graphical analysis illustrating the median values in minutes for the monolithic esomeprazole enteric capsules according to Examples 6 and 7 compared to the commercial delayed release capsule product with enteric coated pellets.
  • the enteric drug delivery system described herein comprises a monolithic enteric capsule filled with at least one active pharmaceutical ingredient (API), wherein the API is without enteric coating for modified release or gastric protection, and wherein said delivery system provides a short intestinal release time period and faster absorption rate following a lag time for release of said API upon administration to a human.
  • API active pharmaceutical ingredient
  • the present disclosure provides a method of increasing bioavailability of an active pharmaceutical ingredient (API), comprising administration to a human in need thereof a therapeutically effective amount of at least one API in a monolithic enteric capsule, wherein said API is without enteric coating and wherein said delivery system provides a short intestinal release time period and a faster absorption rate following a lag time for release of said API, and wherein the bioavailability of said API is increased compared to API dosage forms with enteric-coated granules (pellets) of esomeprazole.
  • API active pharmaceutical ingredient
  • Certain embodiments comprise a system for the delivery of at least one acid labile active pharmaceutical ingredient by administering to a fasting subject an oral dosage form comprising a monolithic enteric capsule filled with the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient has not been enterically coated for modified release or gastric protection, wherein less than about 10% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 2 hours in a pH of about 1.2, wherein at least about 80% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 30 min at pH of about 6.8, and wherein more than about 95% of the active ingredient is released in the intestine.
  • Certain embodiments comprise a system for the delivery of at least one active pharmaceutical ingredient that causes gastric side effects in a fasting subject by administering to said subject an oral dosage form comprising a monolithic enteric capsule filled with the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient has not been enterically coated for modified release or gastric protection, wherein less than about 10% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 2 hours in a pH of about 1.2, wherein at least about 80% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 30 min at pH of about 6.8, and wherein more than about 95% of the active ingredient is released in the intestine so that gastric side effects are reduced or eliminated.
  • the present disclosure is also directed to a system wherein the monolithic enteric capsule yields a peak plasma concentration (C max ) is equal to or higher than the peak plasma concentration achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where C max is increased by up to about 279%.
  • C max peak plasma concentration
  • the monolithic enteric capsule yields an Area Under Curve (AUC 0-t ) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC 0-t achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC 0-t is increased up to about 220%.
  • AUC 0-t Area Under Curve
  • the monolithic enteric capsule yields an Area Under Curve (AUC 0- ⁇ ) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC 0- ⁇ achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC 0- ⁇ is increased up to about 162%.
  • AUC 0- ⁇ Area Under Curve
  • the monolithic enteric capsule has an increase in oral bioavailability from about 10% to about 50% on average compared to bioavailability of the active pharmaceutical ingredient in an oral dosage form comprising at least one enteric coating for modified release or gastric protection.
  • the active pharmaceutical ingredient is a proton pump inhibitor.
  • the active pharmaceutical ingredient is selected from the group consisting of dexlanzoprazole, esomeprazole, ilaprazole, leminoprazole, lanzoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole and combinations, pharmaceutically acceptable salts, derivatives, and enantiomers thereof.
  • the active pharmaceutical ingredient is esomeprazole or its salt.
  • Certain embodiments comprise methods of increasing the bioavailability of an active pharmaceutical ingredient (API), comprising administration to a human in need thereof a therapeutically effective amount of at least one API in a monolithic enteric capsule, wherein said API has not been coated for modified release or gastric protection, wherein the bioavailability of said API is increased compared to API having an enteric coating for modified release or gastric protection.
  • the API having an enteric coating comprises at least one of beads, pellets, granules, and spheres coated with an enteric coating for modified release or gastric protection.
  • the API is acid labile.
  • the API has gastric side effects.
  • Certain embodiments comprise an oral pharmaceutical dosage form comprising a monolithic enteric hard capsule filled with at least one proton pump inhibitor, wherein the monolithic enteric hard capsule yields a peak plasma concentration higher than the peak plasma concentration achieved by the proton pump inhibitor having an enteric coating for modified release or gastric protection.
  • the proton pump inhibitor lacking an enteric coating for modified release or gastric protection comprises uncoated esomeprazole selected from beads, pellets, granules, spheres, and combinations thereof.
  • Certain embodiments comprise a monolithic enteric capsule made by dip molding from an aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the polymer is present in an amount ranging from about 15% to about 25% by weight of the total weight of the aqueous composition; at least one dispersant in an amount ranging from about 0.5% to about 2% by weight of the total weight of said aqueous composition; at least one gelling agent present in an amount ranging from about 0.1% to about 5% by weight of the total weight of said aqueous composition; and water; and wherein the dispersed polymer is partially neutralized with at least one alkaline material.
  • HPMCAS hydroxypropyl methyl cellulose acetate succinate
  • Certain embodiments comprise a monolithic enteric capsule made with a non-salified functional polymer, said polymer being present in an amount ranging from about 50% to about 75% by weight of the total weight of the empty capsule; at least one processing aid present in an amount ranging from about 10.5% to about 20% by weight of the total weight of the empty capsule; and water present in an amount ranging from about 1% to about 20% by weight over the total weight of the empty capsule.
  • Certain embodiments comprise a monolithic enteric capsule comprising cellulose acetate phthalate (CAP), in an amount ranging from about 40% to about 70% by weight; and at least one processing aid selected from polyoxyethylene-polyoxypropylene-polyoxyethylene tri-block polymers and mixtures thereof, and having an average molecular weight ranging from about 1000 to about 20000 and a polyoxyethylene ratio ranging from about 10% to about 80%, in an amount ranging from about 15% to about 49% by weight.
  • CAP cellulose acetate phthalate
  • the monolithic enteric capsule for use in any of the systems and/or methods of the present disclosure lacks internal excipients. In certain embodiments, the monolithic enteric capsule remains substantially intact in the stomach.
  • the dosage form has an oral bioavailability that is about 10% to about 50% higher than the bioavailability of esomeprazole pellets or tablets having an enteric coating for modified release or gastric protection.
  • Certain embodiments comprise a method for delivering esomeprazole to a fasting patient in need thereof, comprising administering to said patient an oral pharmaceutical dosage form comprising a monolithic enteric hard capsule filled with esomeprazole, wherein said esomeprazole has not been enterically coated for modified release or gastric protection, wherein more than about 95% of the esomeprazole is released from the capsule in the intestine, and wherein the pharmacokinetic profile exhibits a C max of from about 700 ng/mL to about 2000 ng/mL, and a mean area under the plasma concentration-time curve from administration to about 12 hours (AUC 0-12 ) from about 800 ng ⁇ h/mL to about 5000 ng ⁇ h/mL.
  • Certain embodiment comprise a dosage form comprising esomeprazole, wherein said esomeprazole has not been enterically coated for modified release or gastric protection, wherein the dosage form exhibits a pharmacokinetic profile in a fasting patient wherein more than about 95% of the esomeprazole is released from the capsule in the intestine, and wherein the pharmacokinetic profile exhibits a C max of from about 700 ng/mL to about 2000 ng/mL, and a mean area under the plasma concentration-time curve from administration to about 12 hours (AUC 0-12 ) from about 800 ng ⁇ h/mL to about 5000 ng ⁇ h/mL.
  • AUC 0-12 mean area under the plasma concentration-time curve from administration to about 12 hours
  • Certain embodiments are directed to methods of improving treatment of a gastrointestinal disorder in a human or other animal in need thereof, comprising administration of a monolithic enteric dosage form according to any of the preceding claims.
  • the monolithic enteric capsule for use in any of the preceding claims, wherein the monolithic enteric capsule provides an increased rate of absorption the active pharmaceutical ingredient after administration to a patient as compared to the rate of absorption of the active pharmaceutical ingredient having an enteric coating for modified release or gastric protection.
  • the monolithic enteric capsule provides an increased rate of absorption C max /(T max ⁇ T lag ) for the active pharmaceutical ingredient after administration to a patient as compared to the rate of absorption of the active pharmaceutical ingredient having an enteric coating for modified release or gastric protection from about 30 ng/mL/hr to about 3400 ng/mL/hr.
  • the monolithic enteric capsule decreases the time to achieve peak plasma concentration (T max ⁇ T lag ) for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably decreasing by from about 0.1 hour to about 2.0 hours. In certain embodiments, the monolithic enteric capsule decreases the time to achieve peak plasma concentration for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably decreasing by from about 10 minutes to about 90 minutes.
  • T max ⁇ T lag peak plasma concentration
  • the monolithic enteric capsule provides an increased lag time after administration to a patient for release of the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably where the increase in lag time is from about 0.1 hour to about 4.3 hours.
  • the treatment of gastrointestinal disorders is improved. These improvements may arise from, for example, faster and more complete release of the active ingredient, more effective application of the active ingredient(s) to the proper portion of the gastrointestinal tract, improved patient compliance, and decreased side effects.
  • administering refers to any method which delivers the dosage forms used in this disclosure to the subject in need thereof so as to be effective in the treatment of the disorder desired to be treated or ameliorated. Oral administration of the dosage forms and administration via the stomach to the intestine and/or colon are of particular interest.
  • AUC “Area Under Curve” or “AUC” refers to the area under the concentration-versus-time curve obtained by plotting the serum or plasma concentration of an active ingredient along the ordinate (Y-axis) against time along the abscissa (X-axis) for a defined time period.
  • the values for AUC represent a number of values taken from all the subjects in a subject test population and are, therefore, mean values averaged over the entire test population.
  • AUC 0-t is the area under the plasma concentration versus time curve from time 0 (administration) to time t
  • AUC 0- ⁇ is the area under the plasma concentration versus time curve from administration to infinity.
  • C max represents the maximum drug concentration in serum or plasma of the test subject.
  • T max is the time after administration of an active ingredient when the maximum plasma concentration is reached.
  • CV is the coefficient of variability.
  • K el is the elimination rate constant.
  • t 1/2 is the elimination half-life.
  • APIs suitable for the present disclosure include APIs with a delivery profile which requires, or benefits from, a lag time followed by a short intestinal release time period.
  • Non-limiting examples of such APIs include drugs that are metabolized to pharmacological active compounds, drugs which have long in vivo half-lives showing an inherently prolonged duration of action, drugs with very short in vivo half-lives which require a prohibitively large amount of active ingredients in a single dosage form, drugs which require large doses for therapeutic effect, drugs which are required in very low doses, and drugs used in chronotherapy, e.g., medications taken at night whose actions are required in the early morning hours, drugs for local gastrointestinal effects, drugs with upper intestine absorption windows, and drugs that undergo extensive first pass metabolism.
  • Classes of active ingredients suitable for the present disclosure include but are not limited to antibiotics, anti-inflammatory drugs, anti-hypertensives, anti-anginal drugs, anti-neoplastic drugs, peptides, proteins, anti-rejection drugs, corticosteroids, anti-arthritics, anti-asthmatics, anti-sense oligonucleotides, and combinations thereof.
  • active ingredients suitable for the present disclosure include but are not limited to combination therapies such as ATRIPLA® (BMS; efavirenz, emtricitabine, tenofovir disoproxil fumarate), TRUVADA® (tenofovir DF and emtriva); VYTORIN® (Merck, ezetimibe/simvastatin combination) and contraceptives such as YAZ® (Bayer, drospirenone and ethinyl estradiol).
  • combination therapies such as ATRIPLA® (BMS; efavirenz, emtricitabine, tenofovir disoproxil fumarate), TRUVADA® (tenofovir DF and emtriva); VYTORIN® (Merck, ezetimibe/simvastatin combination) and contraceptives such as YAZ® (Bayer, drospirenone and ethinyl estradiol).
  • the active ingredient is actonel, amlodipine, 5-amino-salicylic acid, amylin, anastrozole, anidulafungin, aripiprazole, Atosiban, Bacitracin, bivalirudin, bleomycin, bromophenaramine, budesonide, candesartan, capecitabine, caspofungin, Cialis (tadalafil), conotoxin, Colistin, Crestor, cyclosporin, daptamycin, desmopressin, diovan, donepezil HCl, doxorubicin, Enfuvirtide, epoetin, eptifibatide, erlotinib, escitalopram, fenofibrate, 5-fluorouracil, Glucagon-like peptide-1 (GLP-1) AGONIST (e.g., exenatide and liraglutide), glucagon-like
  • the active ingredient is a proton pump inhibitor, including but not limited to dexlanzoprazole, esomeprazole, ilaprazole, lanzoprazole, leminoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole, and pharmaceutically acceptable combinations, salts, derivatives or enantiomers thereof.
  • the active ingredient is esomeprazole in pellet form, without enteric coating.
  • Enteric coating refers to the process and result of coating a dosage form for modified release or gastric protection, and does not include banding or sealing of a telescoping capsule so as to prevent separation of the two capsule halves. “Enteric” as used herein includes delivery to any area of the small intestine and/or the colon. “Uncoated” as used herein refers to the lack of enteric coating, i.e., lacking a coating designed to provide modified release or gastric protection.
  • stomach side effects includes both stomach and esophageal effects, including irritation, erosion, inflammation, ulcerations, pain, reflux, and other undesirable effects.
  • Hard capsules for use in certain embodiments include any telescoping, two piece capsule with bulk enteric and/or delayed release properties and can include capsules with acid resistant properties.
  • Such capsules include but are not limited to capsules according to WO 2012/056321, PCT/EP2013/055302, PCT/EP2013/055298, hereby incorporated by reference in their entirety, and DRCAPSTM acid resistant capsules (Capsugel).
  • the capsules according to certain embodiments of the present disclosure are sufficiently stable for administration to humans and other animals, and display good mechanical properties, i.e., no cracking, discoloring, sticking, and/or deformation.
  • gastrointestinal disorder relates to any infection, disease or other disorder of the gastrointestinal system, such as the upper and/or lower gastrointestinal tract.
  • Such disorders include one or more of the following conditions: diarrhea, heartburn, indigestion, upset stomach, abdominal pain and/or cramping, flatulence, nausea, abdominal distention, fever, constipation, blood, mucus and/or pus present in feces, vomiting, gastroenteritis, weight loss, anorexia, malaise, and any other related condition.
  • “Monolithic enteric dosage form” relates to enteric hard capsules, formed by molding, and filled with an API, to protect the API from stomach acid and to provide release of the API in the intestine of a mammal after administration.
  • Monolithic enteric dosage forms or capsules exhibit these characteristics in the absence of any enteric coating, either on the capsule shell or on the API formulation.
  • Additional components or excipients may optionally be filled within the enteric hard capsules, such as other active ingredients and/or other excipients, for example, diluents, fillers, glidants, lubricants, disintegrants, or any other pharmaceutically suitable formulation excipients.
  • the API alone is filled into the monolithic enteric capsules.
  • Certain embodiments of the monolithic enteric capsules may advantageously be sealed, by application of a sealing solution to the hard capsules by hand, or by automatic or mechanical means such as LEMS® 70 System liquid encapsulation microspray sealing, and CFS technology (CFS 1200 liquid capsule filling and sealing system and CFS 1500C containment capsule filling and sealing system) available from Capsugel. See, e.g., U.S. Pat. No. 7,645,407; EP 2083787.
  • the seals or bands of monolithic enteric capsules are not a coating or an enteric coating, because it is not applied to the entire capsule and it is not intended to modify release or provide gastric protection.
  • the clinical advantages of a system according to the present disclosure include increased absorption and higher bioavailability than a conventional immediate release or sustained release API due to the system's ability to release the API in a burst manner, enhanced delivery of poorly bioavailable drugs that would be destroyed in the higher gastrointestinal tract environment (for example, peptide molecules), reduced dose requirements of API without decrease in therapeutic effect, reduced side effects, reduced drug interactions due to lower receptor concentration of cytochrome P450 isoenzymes, reduced food effect (bioavailability changes of drug when given with food), improved patient compliance, chronotherapy-programmed delayed release of a drug for optimal treatment of disease, pulsatile release, which allows multiple dosing in a single dosage form; and site-specific intestinal release for local treatment of diseases.
  • poorly bioavailable drugs that would be destroyed in the higher gastrointestinal tract environment (for example, peptide molecules)
  • reduced dose requirements of API without decrease in therapeutic effect for example, reduced side effects, reduced drug interactions due to lower receptor concentration of cytochrome P450 isoenzymes
  • reduced food effect bio
  • the technological advantages of a system according to the present disclosure include protection of the API until its arrival at the intestinal site of release; separation of the API release from release variability caused by changes in the pH of the gastrointestinal tract; and separation of drug release from variability caused by changes of lumen content viscosity, because the system is not dependent on the agitation rate of the GI tract.
  • Other advantages are that the system is not colon flora dependent and is not dependent on the nature of the drug.
  • the system offers many parameters for controlling the release profile and the lag time. See, e.g., Pragna et al.
  • the monolithic enteric capsule may contain any solid dosage form such as beads, caplets, capsules, granules, microparticles, multiparticulates, microspheres; powders, pellets, solid lipid pellets, tablets, and combinations thereof, so long as the solid dosage form fits inside the particular hard capsule monolithic enteric capsule.
  • Enteric capsules were manufactured according to established dip molding procedures according to WO 2012/056321, incorporated herein in its entirety by reference.
  • the finished capsules comprised approximately 65% cellulose acetate phthalate (CAP), 20% poloxamer 188, 9% hydroxypropyl methyl cellulose acetyl succinate (HPMC-AS LF), with less than approximately 5% other excipients (including opacifier).
  • CAP cellulose acetate phthalate
  • HPMC-AS LF 9% hydroxypropyl methyl cellulose acetyl succinate
  • After filling with active ingredients the monolithic enteric capsules were banded with a water/ethanol CAP solution using standard techniques.
  • Esomeprazole was filled into capsules as pure esomeprazole magnesium trihydrate powder for comparative dissolution testing (pure EMT).
  • Esomeprazole was formulated as a powder blend by mixing 7.43% (w/w), 22.3 mg/capsule of esomeprazole magnesium trihydrate powder with microcrystalline cellulose (grade Vivapur® 302, JRS Pharma) (91.57%% (w/w), 274.1 mg/capsule) with a 3-dimensional blender for 30 minutes at 60 rpm. Magnesium stearate (1% (w/w), 3 mg/capsule) was added with 10 minutes of additional mixing at 60 rpm. The resulting powder blend EMT was filled into capsules (powder blend EMT).
  • Esomeprazole was formulated as EMT uncoated pellets by preparing an aqueous coating solution and coating onto sugar spheres (lacking enteric coating).
  • the aqueous solution was formed by adding polysorbate 80 (Tween® 80, Croda) to water (approximately 5 times the weight of hydroxypropyl methyl cellulose, HPMC) under gentle stirring (330 rpm) until complete dissolution.
  • HPMC powder HPMC 2010, PHARMACOAT® 606, Shin-Etsu
  • the EMT aqueous suspension of HPMC/polysorbate 80/EMT/water was prepared in a ratio of approximately 10.5/1/44.5/160. EMT powder blend was added in several steps to the HPMC/polysorbate 80/water solution under vigorous stirring (1200 rpm).
  • inert beads sucgar spheres, grade 850-1000 micrometers, JRS Pharma
  • the final composition of the uncoated pellets for a 20 mg esomeprazole dose per capsules is EMT 21.56% (w/w), 22.3 mg; HPMC 5.09% (w/w), 5.25 mg; polysorbate 80 0.48% (w/w), 0.5 mg; and sugar spheres, 72.87% (w/w), 75.2 mg.
  • the 40 mg EMT uncoated pellet monolithic enteric capsules were filled with 206.4 mg of uncoated pellets, and banded as described in Example 1.
  • Tested capsules prepared according to Examples 1-4 were filled with pure EMT, EMT uncoated pellets, or powder blend EMT equivalent to 20 mg of esomeprazole.
  • the commercial product delayed release capsule is coated pellets within a gelatin capsule, wherein the internal enteric coated pellet formulation has glyceryl monostearate 40-55, hydroxypropylcellulose (HPC), hypromellose (HPMC), magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sugar spheres, talc and triethyl citrate in a gelatin capsule (NEXIUM® patient leaflet, 2012).
  • the commercial product is also available as a tablet (NEXIUM® tablets, “Multiple Unit Pellet System” or MUPS).
  • the tablet's complex composition includes 17 excipients, starting from the same enteric coated pellets in the delayed release capsule form plus microcrystalline cellulose, hard paraffin hard, Macrogol 6000, crospovidone, sodium stearyl fumarate, and colorants (NEXIUM® tablets MUPS, patient leaflet, 2011).
  • the dissolution method was performed according to the USP monograph for Esomeprazole Magnesium Delayed-Release Capsule. Briefly, capsules were tested in apparatus 2 at 100 rpm, with sinker, at 37° C. ⁇ 0.5° C., wherein the acid stage is 2 hours in 300 mL of 0.1 N HCl medium, followed by the buffer stage which is the addition of 700 mL of 0.086M dibasic sodium phosphate to adjust the pH to 6.8. The requirements under the specifications are during the acid stage no unit more than 10% dissolved after 2 hours in 0.1N HCl medium, and buffer stage no unit less than 80% (Q+5%) dissolved after 30 min at pH 6.8. The measured results were the % EMT dissolved relative to the initial label claim/capsule dosage (20 mg).
  • the pharmacopeia specifications for esomeprazole magnesium delayed release capsules were reached. Therefore, the monolithic enteric capsules showed excellent enteric release containing a powdered blend of an acid sensitive active ingredient, and without any need for enteric coating. This dissolution result closely resembled the commercial tablet and capsule product results.
  • the EMT in the EMT uncoated pellets prepared according to Example 2, filled into the monolithic enteric capsules of Example 1, and tested according to the dissolution protocol of Example 3, showed no release of EMT in the acid stage and the capsule itself did not dissolve during the acid stage (three trials, 120 minute mean was 0%, n 6 each trial), the dissolution medium remained clear.
  • the pharmacopeia specifications for esomeprazole magnesium delayed release capsules were reached. Therefore, the monolithic enteric capsules showed excellent enteric release containing uncoated pellets of an acid sensitive active ingredient, and without any need for enteric coating. This dissolution result equaled or exceeded the commercial tablet and capsule product results.
  • Monolithic enteric capsules were prepared according to Example 2, but sufficient uncoated pellets were added to provide a 40 mg esomeprazole dose.
  • Radiolabelling was provided by adding approximately 4 MBq 99m Tc (Technetium-99m, West of Scotland Radionuclide Dispensary, Glasgow) as a radioactive tracer, measured at the time of dosing.
  • a suitable dose of radioactivity (0.3 mSv in total) was chosen to provide a signal of adequate quality while exposing the subjects to the minimum possible radiation.
  • Non-disintegrating pellets labeled with technetium-99m pertechnetate were added into each capsule (both the tested capsules and the commercial product) to allow scintigraphic monitoring.
  • Scintigraphy imaging via gamma camera was performed according to standard medical diagnostic testing procedures with anterior and posterior images acquired at initial dosing and at regular time intervals post initial dosing. Specifically, anterior and posterior images of 25 seconds each were acquired at dosing, then every 10 minutes to 2 hours post-dose, then every 15 minutes to 5 hours post-dose, then every 30 min to 12 hours post-dose with the subjects (standing position, Siemens E-Cam gamma camera fitted with a low-energy high-resolution collimator). Pharmacokinetic information was obtained via blood sampling pre-dose and at regular time intervals post initial dosing according to established procedures.
  • the radiolabelled capsules both Example 6 and commercial capsules
  • Subjects were dosed standing up and instructed to swallow the capsule whole with 240 mL room temperature water.
  • Table 1 illustrates the comparative location of release in vivo as determined from the scintigraphic imaging, and confirms enteric release of the monolithic enteric capsules under a fasting state. All of the Example 6 capsules released in either the small intestine or the ileocecal junction, and none released in the stomach. In contrast, all of the commercial capsule product tested in patients released in either the esophagus or the stomach (as expected from use of immediate release gelatin capsules). No capsules failed to release and/or remained in the stomach or small intestine after 12 hours for either tested formulation.
  • Table 2 shows the release time profiles for median values given in minutes for the site of release onset under a fasting state as measured by scintigraphic imaging.
  • the monolithic enteric capsules opened only after gastric emptying, but the commercial product, with enteric coated pellets in a gelatin capsule, were released prior to gastric emptying.
  • Monolithic enteric capsules containing EMT uncoated pellets (40 mg) prepared as described in Example 6 were selected for in vivo testing in a randomized, open label, three-treatment, three period, three sequence, crossover, single dose pharmacoscintigraphy study in healthy volunteers and compared to the commercial esomeprazole delayed release capsule NEXIUM® product (Astra Zeneca), which has enterically coated pellets.
  • Time points for plasma sampling were pre-dose and 0.5, 0.75, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, and 12 hours post-dose.
  • BMI Body Mass Index
  • Selected patients were randomized to three treatment arms and three treatment sequences-monolithic enteric capsule fasted state, monolithic enteric capsule fed state, and commercial product fasted state.
  • the crossover design eliminated potential treatment effects on the outcome, as well as effectively allowing the subject to serve as his own control.
  • Each dosing occasion was separated by a 7-14 day washout period.
  • Fasting conditions represented an overnight fast of at least 10 hours and fed state was after a high calorie, high fat breakfast 30 minutes prior to dosing.
  • the % EMT was quantified from human plasma according to methods based on the FDA Bioanalytical Method Validation Guide for Industry and the EMA Guideline on bioanalytical method validation (York Bioanalytical Solutions). Briefly, plasma samples were submitted to supported liquid extraction and liquid chromatography with tandem mass spectrometric detection (lower limit of quantification 5.00 ng/ml with a sample aliquot volume of 100 microliters). The analytes detected were esomeprazole, 5-hydroxyomeprazole, and omeprazole sulphone and were validated against commercial samples and calibration standards. Results obtained with 5-hydroxyomeprazole and omeprazole sulphone were similar to esomeprazole (not shown).
  • Calibration samples were obtained commercially as follows: esomeprazole (Sigma-Aldrich), 5-hydroxyomeprazole, and omeprazole sulphone (Toronto Chemicals Inc.). Internal standards omeprazole d3, 5-hydroxyomeprazole d3 and omeprazole sulphone-d3 were also utilized (Toronto Chemicals Inc.). Plasma samples were stored at ⁇ 20° C. Data was collected using Analyst software (Applied Biosystems-Sciex) in combination with Watson LIMS (Thermo Fisher Scientific); peak area ratios were used to generate calibration curves using regression functions.
  • the in vivo pharmacokinetic results obtained illustrate that the monolithic enteric capsule product surprisingly exhibited a statistically significant delay in onset time of quantifiable plasma concentrations as compared to the multiparticulate, enteric coated commercial dosage form of an acid sensitive active ingredient.
  • This delivery system provides a short intestinal release time period.
  • Table 4 illustrate the faster absorption rate of the uncoated pellets in the enteric capsule compared to the enteric coated beads of the commercial product.
  • C max /(T max ⁇ T lag ) is used to measure the rate of absorption (where T lag equals the measured time prior to the first non-zero drug concentration). Delayed release products are characterized by the fact the drug release is internally delayed. Because of the designed delay, T max alone would have limited meaning as a rate of absorption characteristic, and T max ⁇ T lag would provide a more meaningful metric. In contrast to T max , C max may not be affected by the delayed release.
  • Esomeprazole in uncoated pellets in a monolithic enteric capsule prepared according to Example 6 showed a significant difference in vivo between C max /(T max ⁇ T lag ) compared to the commercial product of enteric coated pellets in a gelatin capsule (P value ⁇ 0.05), based upon actual hours post-dose and individual time points.
  • Example 6 monolithic enteric capsules compared to the commercial product showed an increase in C max of 56% in in vivo testing, with a ratio of 155.75% (90% confidence interval 86.93, 279.07, geometric least squares means).
  • the ratio of the Example 6 monolithic enteric capsules compared to the commercial product showed an increase in AUC of 132% in in vivo testing, with a ratio of 131.67% (90% confidence upper interval 220.96, geometric least squares means).
  • the rate of drug elimination was similar after release into the gastrointestinal tract, i.e., Example 6 vs. commercial product was Kei (1/h) 0.593 ( ⁇ 0.149) vs. 0.60 ( ⁇ 0.203).
  • the fed samples provided a delayed release beyond the test period.
  • Food effect delay is known from the commercial product, which is designated to be taken at least one hour before meals.
  • the high fat meal did not affect the integrity of the Example 6 capsules within the stomach.
  • Table 5 provides the means and standard deviation for the pharmacokinetic parameters for the Example 6 samples, fed and fasted, compared to the commercial product (enteric coated pellets in a capsule).
  • Table 6 shows the variability of the pharmacokinetic parameters obtained according to Examples 6 and 7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Application No. 61/899,586, filed Nov. 4, 2013, which is incorporated herein by reference in its entirety.
  • FIELD
  • The present disclosure relates to delivery systems and methods for increasing the bioavailability of active ingredients by oral monolithic enteric capsule administration to humans, particularly the administration of acid sensitive active ingredients such as omeprazole, esomeprazole, and other proton pump inhibitors, methods to deliver active pharmaceutical ingredients to humans or animals via hard capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.
  • BACKGROUND
  • Modification of drug absorption has important implications for efficacy, tolerability, compliance and toxicity. Variable and delayed release drug delivery systems have been pursued for mimicking biological processes as well as for defining administration timing and location parameters. Many complicated systems have been proposed and some have been executed in the modified release field; however, rapid drug release after a defined lag time remains a “major challenge.” Pragna, Pulsatile Drug Delivery System: An Overview, Int. J. Pharmaceutical Dev. & Technol., 3(2): 97-105 (2013). Such lag time/pulsatile release delivery systems include various types and combinations of osmotic pumps, multiple coatings, plugs, orifices, tablets, and barriers. All of these prior systems require significant development time and formulation expertise.
  • Multiparticulate dosage forms, with multiple release sites for active pharmaceutical ingredients, are expected to provide faster release rate profiles in blood than monolithic dosage forms such as capsules. Residence time in the stomach strongly depends on the composition of the dosage form and the presence of food components, and multiparticulate dosage forms are expected to be emptied from the stomach quickly, on a similar time scale as solutions, i.e., within 10 to 60 minutes in a fasted state, or within 1-2 hours under a fed state. Gastric emptying of a monolithic solid dosage form is delayed under a fed state, with a range of 4-7 hours depending on the caloric content of the meal. Gastric emptying time is shorter for multiparticulate dosage forms than for monolithic solid dosage forms, leading to correspondingly delayed pK values in blood for a monolithic dosage form.
  • Capsules are monolithic dosage forms widely used in the pharmaceutical field for oral administration to humans and animals of, e.g., various active ingredients, including pharmaceuticals, veterinary products, and food and dietary supplements. Advantages of capsules over other conventional dosage forms (such as tablets or liquids) may include better patient compliance, greater flexibility in dosage form design, taste masking, and less expensive manufacturing processes.
  • Capsules normally consist of a shell filled with one or more specific substances. The shell itself may be a soft or a hard capsule shell. Hard capsule shells are generally manufactured using dip molding processes, which can be distinguished into two alternative procedures. In the first procedure, capsules are prepared by dipping stainless-steel mold pins into a solution of polymer, optionally containing one or more gelling agents (e.g. carrageenans) and co-gelling agents (e.g. inorganic cations). The mold pins are subsequently removed, inverted, and dried to form a film on the surface. The dried capsule films are then removed from the molds, cut to the desired length, and then the telescoping fit caps and bodies are assembled together, printed, and packaged. See, e.g., U.S. Pat. Nos. 5,264,223, 5,756,123, and 5,756,123. In the second procedure, no gelling agents or co-gelling agents are used and film-forming polymer solution gelification on the molding pins is thermally induced by dipping pre-heated molding pins into the polymer solution. This second process is commonly referred to as thermogellation, or thermogelling dip molding. See, e.g., EP 0401832, U.S. Pat. Nos. 3,493,407, 4,001,211, and 3,617,588, GB 1310697, and WO 2008/050209. The aforementioned manufacturing processes involve the use of solutions of the different ingredients that are needed for the making the telescoping fit hard capsule shells.
  • Hard capsules may be filled with active ingredients via procedures known in the art. Typically, active ingredients are combined with various compatible excipients for ease of fill. The resulting fill may be a dry powder, a granulation, pellets, lipid pellets, a suspension, or a liquid. Additionally, stable, filled hard capsules have advantages over other dosage delivery forms such as liquids and solid tablets. Certain active ingredients may be difficult to formulate into dry granules, or may be otherwise incompatible with the tableting process. Another consideration is improved patient compliance for taste-masking and ease of swallowing, i.e., capsules being preferred by consumers over tablets.
  • Acid labile or acid sensitive active ingredients, active ingredients associated with gastric damage or upset, or active ingredients which degrade in the stomach, may require particular formulation steps to prevent active ingredient degradation and/or irritation of the stomach mucosa. Such formulation steps include enteric coating, either of multiparticulates or granules, or of tablets formed from direct compaction and/or granulation of the active ingredients. Additional processing steps (such as granulation, coating, and/or tableting) add manufacturing complexity and resultant cost to pharmaceutical dosage forms. Other disadvantages include undesirable interaction with the enteric coating itself. For example, methacrylic acid copolymer, a common enteric coating, has multiple acid groups, and thus must be separated from acid sensitive active ingredients, for example, by pre-coating or protective coating in addition to an enteric coating layer, increasing the time, cost and complexity of the resulting dosage forms, whether granules, pellets, or tablets.
  • Another method for protecting acid sensitive active ingredients from degradation is the addition of a pH neutralizing agent, such as high levels of sodium bicarbonate, see, e.g., ZEGERID® (omeprazole product from Santarus). While such a formulation avoids the need for a coating step, these buffer-containing dosage forms have a high sodium content (inadvisable for patients on sodium restricted diets) and the need for a large amount of neutralizing agent results in a high formulation weight requiring a large capsule size, at least capsule size #0.
  • While hard capsules may be coated in order to change the release characteristics of the capsule, such coatings require additional processing steps and are only able to be completed after active ingredient filling of a hard capsule. In addition, the amount and the character of the coating must be adjusted by the end user for each formulation so that the desired characteristics are obtained.
  • Proton pump inhibitors are acid labile and may be the cause of gastric discomfort, and include compounds such as dexlanzoprazole, esomeprazole, ilaprazole, leminoprazole, lanzoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole and pharmaceutically acceptable salts, derivatives and enantiomers thereof are known. Proton pump inhibitors are prescribed for the treatment of gastric-acid related diseases such as reflux esophagitis, gastric and duodenal ulcers, Zollinger-Ellison syndrome, and treatment of H. pylori infections. Various proton pump inhibitor compounds are known and sold commercially. The use of such compounds in enteric coated pellet form has been disclosed, for example in U.S. Pat. No. 5,877,192 incorporated in its entirety herein.
  • Esomeprazole (also known as perprazole, omeprazole S-form, and (−)-omeprazole) compositions are also commercially available, for example, sold under the trademark NEXIUM® (Astra Zeneca) in 20 mg and 40 mg doses, in tablet and capsule forms. Esomeprazole (as the magnesium trihydrate, C34H36MgN6O6S2.3H2O) has a molecular weight of 767.17 g/mol and is slightly soluble in water (1.5 mg/ml in water at 25° C.), soluble in methane and insoluble in heptane. Esomeprazole degrades in acid conditions but is stable at pH 6.8. Typical pharmaceutically effective amounts of esomeprazole for administration to humans range from about 5 mg to about 80 mg, administered once or twice daily.
  • U.S. Pat. No. 5,714,504 to Lindberg describes optically pure salts of omeprazole and methods for their use.
  • U.S. Patent Publication No. 2006/0280795 to Penhasi describes a delivery device for the delayed release of an active agent in the gastrointestinal tract with multiple coating and polymer layers.
  • DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the mean plasma concentrations for 14 patients versus time for the monolithic esomeprazole enteric capsules without enteric coating (fed and fasted) according to Examples 6 and 7 and for the commercial delayed release capsule product with enteric coated pellets.
  • FIG. 2 is a stick plot comparing the Cmax (fasted) for the monolithic esomeprazole enteric capsule without enteric coating to the commercial delayed release capsule product with enteric coated pellets for each patient.
  • FIG. 3 is a graphical analysis illustrating the median values in minutes for the monolithic esomeprazole enteric capsules according to Examples 6 and 7 compared to the commercial delayed release capsule product with enteric coated pellets.
  • DETAILED DESCRIPTION
  • The system and methods of the instant disclosure provide a faster absorption rate and shorter absorption times than the multiparticulate enteric coated dosage form. In one aspect, the enteric drug delivery system described herein comprises a monolithic enteric capsule filled with at least one active pharmaceutical ingredient (API), wherein the API is without enteric coating for modified release or gastric protection, and wherein said delivery system provides a short intestinal release time period and faster absorption rate following a lag time for release of said API upon administration to a human.
  • In another aspect, the present disclosure provides a method of increasing bioavailability of an active pharmaceutical ingredient (API), comprising administration to a human in need thereof a therapeutically effective amount of at least one API in a monolithic enteric capsule, wherein said API is without enteric coating and wherein said delivery system provides a short intestinal release time period and a faster absorption rate following a lag time for release of said API, and wherein the bioavailability of said API is increased compared to API dosage forms with enteric-coated granules (pellets) of esomeprazole.
  • Certain embodiments comprise a system for the delivery of at least one acid labile active pharmaceutical ingredient by administering to a fasting subject an oral dosage form comprising a monolithic enteric capsule filled with the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient has not been enterically coated for modified release or gastric protection, wherein less than about 10% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 2 hours in a pH of about 1.2, wherein at least about 80% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 30 min at pH of about 6.8, and wherein more than about 95% of the active ingredient is released in the intestine.
  • Certain embodiments comprise a system for the delivery of at least one active pharmaceutical ingredient that causes gastric side effects in a fasting subject by administering to said subject an oral dosage form comprising a monolithic enteric capsule filled with the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient has not been enterically coated for modified release or gastric protection, wherein less than about 10% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 2 hours in a pH of about 1.2, wherein at least about 80% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 30 min at pH of about 6.8, and wherein more than about 95% of the active ingredient is released in the intestine so that gastric side effects are reduced or eliminated.
  • In certain embodiments, the present disclosure is also directed to a system wherein the monolithic enteric capsule yields a peak plasma concentration (Cmax) is equal to or higher than the peak plasma concentration achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where Cmax is increased by up to about 279%.
  • In certain embodiments, the monolithic enteric capsule yields an Area Under Curve (AUC0-t) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC0-t achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC0-t is increased up to about 220%.
  • The system according to any of the preceding claims, wherein the monolithic enteric capsule yields an Area Under Curve (AUC0-∞) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC0-∞ achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC0-∞ is increased up to about 162%.
  • In certain embodiments, the monolithic enteric capsule has an increase in oral bioavailability from about 10% to about 50% on average compared to bioavailability of the active pharmaceutical ingredient in an oral dosage form comprising at least one enteric coating for modified release or gastric protection.
  • In certain embodiments, the active pharmaceutical ingredient is a proton pump inhibitor. In certain embodiments, the active pharmaceutical ingredient is selected from the group consisting of dexlanzoprazole, esomeprazole, ilaprazole, leminoprazole, lanzoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole and combinations, pharmaceutically acceptable salts, derivatives, and enantiomers thereof. In certain embodiments, the active pharmaceutical ingredient is esomeprazole or its salt.
  • Certain embodiments comprise methods of increasing the bioavailability of an active pharmaceutical ingredient (API), comprising administration to a human in need thereof a therapeutically effective amount of at least one API in a monolithic enteric capsule, wherein said API has not been coated for modified release or gastric protection, wherein the bioavailability of said API is increased compared to API having an enteric coating for modified release or gastric protection. In certain embodiments, the API having an enteric coating comprises at least one of beads, pellets, granules, and spheres coated with an enteric coating for modified release or gastric protection. In certain embodiments, the API is acid labile. In certain embodiments the API has gastric side effects.
  • Certain embodiments comprise an oral pharmaceutical dosage form comprising a monolithic enteric hard capsule filled with at least one proton pump inhibitor, wherein the monolithic enteric hard capsule yields a peak plasma concentration higher than the peak plasma concentration achieved by the proton pump inhibitor having an enteric coating for modified release or gastric protection. In certain embodiments, the proton pump inhibitor lacking an enteric coating for modified release or gastric protection comprises uncoated esomeprazole selected from beads, pellets, granules, spheres, and combinations thereof.
  • Certain embodiments comprise a monolithic enteric capsule made by dip molding from an aqueous composition comprising hydroxypropyl methyl cellulose acetate succinate (HPMCAS) polymer dispersed in water, wherein the polymer is present in an amount ranging from about 15% to about 25% by weight of the total weight of the aqueous composition; at least one dispersant in an amount ranging from about 0.5% to about 2% by weight of the total weight of said aqueous composition; at least one gelling agent present in an amount ranging from about 0.1% to about 5% by weight of the total weight of said aqueous composition; and water; and wherein the dispersed polymer is partially neutralized with at least one alkaline material.
  • Certain embodiments comprise a monolithic enteric capsule made with a non-salified functional polymer, said polymer being present in an amount ranging from about 50% to about 75% by weight of the total weight of the empty capsule; at least one processing aid present in an amount ranging from about 10.5% to about 20% by weight of the total weight of the empty capsule; and water present in an amount ranging from about 1% to about 20% by weight over the total weight of the empty capsule.
  • Certain embodiments comprise a monolithic enteric capsule comprising cellulose acetate phthalate (CAP), in an amount ranging from about 40% to about 70% by weight; and at least one processing aid selected from polyoxyethylene-polyoxypropylene-polyoxyethylene tri-block polymers and mixtures thereof, and having an average molecular weight ranging from about 1000 to about 20000 and a polyoxyethylene ratio ranging from about 10% to about 80%, in an amount ranging from about 15% to about 49% by weight.
  • In certain embodiments, the monolithic enteric capsule for use in any of the systems and/or methods of the present disclosure lacks internal excipients. In certain embodiments, the monolithic enteric capsule remains substantially intact in the stomach.
  • In certain embodiments, the dosage form has an oral bioavailability that is about 10% to about 50% higher than the bioavailability of esomeprazole pellets or tablets having an enteric coating for modified release or gastric protection.
  • Certain embodiments comprise a method for delivering esomeprazole to a fasting patient in need thereof, comprising administering to said patient an oral pharmaceutical dosage form comprising a monolithic enteric hard capsule filled with esomeprazole, wherein said esomeprazole has not been enterically coated for modified release or gastric protection, wherein more than about 95% of the esomeprazole is released from the capsule in the intestine, and wherein the pharmacokinetic profile exhibits a Cmax of from about 700 ng/mL to about 2000 ng/mL, and a mean area under the plasma concentration-time curve from administration to about 12 hours (AUC0-12) from about 800 ng·h/mL to about 5000 ng·h/mL.
  • Certain embodiment comprise a dosage form comprising esomeprazole, wherein said esomeprazole has not been enterically coated for modified release or gastric protection, wherein the dosage form exhibits a pharmacokinetic profile in a fasting patient wherein more than about 95% of the esomeprazole is released from the capsule in the intestine, and wherein the pharmacokinetic profile exhibits a Cmax of from about 700 ng/mL to about 2000 ng/mL, and a mean area under the plasma concentration-time curve from administration to about 12 hours (AUC0-12) from about 800 ng·h/mL to about 5000 ng·h/mL.
  • Certain embodiments are directed to methods of improving treatment of a gastrointestinal disorder in a human or other animal in need thereof, comprising administration of a monolithic enteric dosage form according to any of the preceding claims.
  • In certain embodiments, the monolithic enteric capsule for use in any of the preceding claims, wherein the monolithic enteric capsule provides an increased rate of absorption the active pharmaceutical ingredient after administration to a patient as compared to the rate of absorption of the active pharmaceutical ingredient having an enteric coating for modified release or gastric protection.
  • In certain embodiments, the monolithic enteric capsule provides an increased rate of absorption Cmax/(Tmax−Tlag) for the active pharmaceutical ingredient after administration to a patient as compared to the rate of absorption of the active pharmaceutical ingredient having an enteric coating for modified release or gastric protection from about 30 ng/mL/hr to about 3400 ng/mL/hr.
  • In certain embodiments, the monolithic enteric capsule decreases the time to achieve peak plasma concentration (Tmax−Tlag) for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably decreasing by from about 0.1 hour to about 2.0 hours. In certain embodiments, the monolithic enteric capsule decreases the time to achieve peak plasma concentration for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably decreasing by from about 10 minutes to about 90 minutes.
  • In certain embodiments, the monolithic enteric capsule provides an increased lag time after administration to a patient for release of the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably where the increase in lag time is from about 0.1 hour to about 4.3 hours.
  • In some embodiments according to the present disclosure, the treatment of gastrointestinal disorders is improved. These improvements may arise from, for example, faster and more complete release of the active ingredient, more effective application of the active ingredient(s) to the proper portion of the gastrointestinal tract, improved patient compliance, and decreased side effects.
  • “Administering” refers to any method which delivers the dosage forms used in this disclosure to the subject in need thereof so as to be effective in the treatment of the disorder desired to be treated or ameliorated. Oral administration of the dosage forms and administration via the stomach to the intestine and/or colon are of particular interest.
  • “Area Under Curve” or “AUC” refers to the area under the concentration-versus-time curve obtained by plotting the serum or plasma concentration of an active ingredient along the ordinate (Y-axis) against time along the abscissa (X-axis) for a defined time period. Generally, the values for AUC represent a number of values taken from all the subjects in a subject test population and are, therefore, mean values averaged over the entire test population. By measuring the AUC for a population to which the test composition has been administered and comparing it with the AUC for the same population to which the control has been administered, the test composition can be evaluated. AUC's are used in the pharmaceutical arts and have been described, for example, in “Pharmacokinetics Processes and Mathematics”, Peter E. Welling, ACS Monograph 185; 1986. Correspondingly, “AUC0-t” is the area under the plasma concentration versus time curve from time 0 (administration) to time t, and “AUC0-∞” is the area under the plasma concentration versus time curve from administration to infinity. “Cmax” represents the maximum drug concentration in serum or plasma of the test subject. “Tmax” is the time after administration of an active ingredient when the maximum plasma concentration is reached. “CV” is the coefficient of variability. “Kel” is the elimination rate constant. “t1/2” is the elimination half-life.
  • “Active ingredients,” “active pharmaceutical ingredients,” “drugs,” and “API” are used interchangeably herein, and APIs suitable for the present disclosure include APIs with a delivery profile which requires, or benefits from, a lag time followed by a short intestinal release time period. Non-limiting examples of such APIs include drugs that are metabolized to pharmacological active compounds, drugs which have long in vivo half-lives showing an inherently prolonged duration of action, drugs with very short in vivo half-lives which require a prohibitively large amount of active ingredients in a single dosage form, drugs which require large doses for therapeutic effect, drugs which are required in very low doses, and drugs used in chronotherapy, e.g., medications taken at night whose actions are required in the early morning hours, drugs for local gastrointestinal effects, drugs with upper intestine absorption windows, and drugs that undergo extensive first pass metabolism. Classes of active ingredients suitable for the present disclosure include but are not limited to antibiotics, anti-inflammatory drugs, anti-hypertensives, anti-anginal drugs, anti-neoplastic drugs, peptides, proteins, anti-rejection drugs, corticosteroids, anti-arthritics, anti-asthmatics, anti-sense oligonucleotides, and combinations thereof.
  • Other classes of active ingredients suitable for the present disclosure include but are not limited to combination therapies such as ATRIPLA® (BMS; efavirenz, emtricitabine, tenofovir disoproxil fumarate), TRUVADA® (tenofovir DF and emtriva); VYTORIN® (Merck, ezetimibe/simvastatin combination) and contraceptives such as YAZ® (Bayer, drospirenone and ethinyl estradiol).
  • In certain embodiments, the active ingredient is actonel, amlodipine, 5-amino-salicylic acid, amylin, anastrozole, anidulafungin, aripiprazole, Atosiban, Bacitracin, bivalirudin, bleomycin, bromophenaramine, budesonide, candesartan, capecitabine, caspofungin, Cialis (tadalafil), conotoxin, Colistin, Crestor, cyclosporin, daptamycin, desmopressin, diovan, donepezil HCl, doxorubicin, Enfuvirtide, epoetin, eptifibatide, erlotinib, escitalopram, fenofibrate, 5-fluorouracil, Glucagon-like peptide-1 (GLP-1) AGONIST (e.g., exenatide and liraglutide), glucagon, gonadoreline, gramidicin, GV1001, histatin, hydrocortisone, ibuprofen, icatibant, imatinib mesylate, insulin, interferons, isosorbides, lactoferrin, Lanreotide, lisdexamfetamine dimesylate, Lypressin, memantine HCl, mesalamine, metoprolol, methylphenidate, micafungin, Micardis (HCT and telmisartan), MPB8298, mycophenolate sodium, nemifitide nesiritide, nicotine, nifedipine, Octreotide, ofloxacin, olanzapine, olmesartan, omiganan, oxyprenolol, oxytocin, pexiganan, pioglitazone HCl, prednisone, prednisolone, pseudoephedrine, protirelin, risedronate sodium, rotigaptide, sermorelin, saloatonin, somatropin, stimuvax, tacrolimus, tamsulosin, taxotere, Terlipressin, theophylline, Thymalfasin, urotoilitin, and combinations thereof; preferably imatinib mesylate, mesalamine, mycophenate sodium, ibuprofen, insulin, desmopressin, or somatropin, and pharmaceutically acceptable combinations, salts, derivatives or enantiomers thereof.
  • In one embodiment, the active ingredient is a proton pump inhibitor, including but not limited to dexlanzoprazole, esomeprazole, ilaprazole, lanzoprazole, leminoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole, and pharmaceutically acceptable combinations, salts, derivatives or enantiomers thereof. In one embodiment, the active ingredient is esomeprazole in pellet form, without enteric coating.
  • “Enteric coating” as used herein refers to the process and result of coating a dosage form for modified release or gastric protection, and does not include banding or sealing of a telescoping capsule so as to prevent separation of the two capsule halves. “Enteric” as used herein includes delivery to any area of the small intestine and/or the colon. “Uncoated” as used herein refers to the lack of enteric coating, i.e., lacking a coating designed to provide modified release or gastric protection.
  • “Gastric side effects” as used herein includes both stomach and esophageal effects, including irritation, erosion, inflammation, ulcerations, pain, reflux, and other undesirable effects.
  • Hard capsules for use in certain embodiments include any telescoping, two piece capsule with bulk enteric and/or delayed release properties and can include capsules with acid resistant properties. Such capsules include but are not limited to capsules according to WO 2012/056321, PCT/EP2013/055302, PCT/EP2013/055298, hereby incorporated by reference in their entirety, and DRCAPS™ acid resistant capsules (Capsugel). The capsules according to certain embodiments of the present disclosure, are sufficiently stable for administration to humans and other animals, and display good mechanical properties, i.e., no cracking, discoloring, sticking, and/or deformation.
  • As used in the present disclosure, “gastrointestinal disorder” relates to any infection, disease or other disorder of the gastrointestinal system, such as the upper and/or lower gastrointestinal tract. Such disorders include one or more of the following conditions: diarrhea, heartburn, indigestion, upset stomach, abdominal pain and/or cramping, flatulence, nausea, abdominal distention, fever, constipation, blood, mucus and/or pus present in feces, vomiting, gastroenteritis, weight loss, anorexia, malaise, and any other related condition.
  • “Monolithic enteric dosage form” relates to enteric hard capsules, formed by molding, and filled with an API, to protect the API from stomach acid and to provide release of the API in the intestine of a mammal after administration. Monolithic enteric dosage forms or capsules exhibit these characteristics in the absence of any enteric coating, either on the capsule shell or on the API formulation. Additional components or excipients may optionally be filled within the enteric hard capsules, such as other active ingredients and/or other excipients, for example, diluents, fillers, glidants, lubricants, disintegrants, or any other pharmaceutically suitable formulation excipients. In certain embodiments, the API alone is filled into the monolithic enteric capsules.
  • Certain embodiments of the monolithic enteric capsules may advantageously be sealed, by application of a sealing solution to the hard capsules by hand, or by automatic or mechanical means such as LEMS® 70 System liquid encapsulation microspray sealing, and CFS technology (CFS 1200 liquid capsule filling and sealing system and CFS 1500C containment capsule filling and sealing system) available from Capsugel. See, e.g., U.S. Pat. No. 7,645,407; EP 2083787. The seals or bands of monolithic enteric capsules are not a coating or an enteric coating, because it is not applied to the entire capsule and it is not intended to modify release or provide gastric protection.
  • The clinical advantages of a system according to the present disclosure include increased absorption and higher bioavailability than a conventional immediate release or sustained release API due to the system's ability to release the API in a burst manner, enhanced delivery of poorly bioavailable drugs that would be destroyed in the higher gastrointestinal tract environment (for example, peptide molecules), reduced dose requirements of API without decrease in therapeutic effect, reduced side effects, reduced drug interactions due to lower receptor concentration of cytochrome P450 isoenzymes, reduced food effect (bioavailability changes of drug when given with food), improved patient compliance, chronotherapy-programmed delayed release of a drug for optimal treatment of disease, pulsatile release, which allows multiple dosing in a single dosage form; and site-specific intestinal release for local treatment of diseases.
  • The technological advantages of a system according to the present disclosure include protection of the API until its arrival at the intestinal site of release; separation of the API release from release variability caused by changes in the pH of the gastrointestinal tract; and separation of drug release from variability caused by changes of lumen content viscosity, because the system is not dependent on the agitation rate of the GI tract. Other advantages are that the system is not colon flora dependent and is not dependent on the nature of the drug. The system offers many parameters for controlling the release profile and the lag time. See, e.g., Pragna et al.
  • One major advantage is that a system according to the present disclosure is based on standard pharmaceutical hard capsule filling equipment and does not rely on post-filling processing or coating variability. Because the hard capsule itself (without any enteric coating) exhibits the desired enteric properties, active ingredient release is not dependent on the weight ratio of, or interactions between, formulation excipients and active ingredients. The monolithic enteric capsule may contain any solid dosage form such as beads, caplets, capsules, granules, microparticles, multiparticulates, microspheres; powders, pellets, solid lipid pellets, tablets, and combinations thereof, so long as the solid dosage form fits inside the particular hard capsule monolithic enteric capsule.
  • The following examples are merely illustrative, and should not be construed as limiting the present disclosure
  • Example 1
  • Enteric capsules were manufactured according to established dip molding procedures according to WO 2012/056321, incorporated herein in its entirety by reference. The finished capsules comprised approximately 65% cellulose acetate phthalate (CAP), 20% poloxamer 188, 9% hydroxypropyl methyl cellulose acetyl succinate (HPMC-AS LF), with less than approximately 5% other excipients (including opacifier). After filling with active ingredients the monolithic enteric capsules were banded with a water/ethanol CAP solution using standard techniques.
  • Example 2
  • Esomeprazole was filled into capsules as pure esomeprazole magnesium trihydrate powder for comparative dissolution testing (pure EMT).
  • Esomeprazole was formulated as a powder blend by mixing 7.43% (w/w), 22.3 mg/capsule of esomeprazole magnesium trihydrate powder with microcrystalline cellulose (grade Vivapur® 302, JRS Pharma) (91.57%% (w/w), 274.1 mg/capsule) with a 3-dimensional blender for 30 minutes at 60 rpm. Magnesium stearate (1% (w/w), 3 mg/capsule) was added with 10 minutes of additional mixing at 60 rpm. The resulting powder blend EMT was filled into capsules (powder blend EMT).
  • Esomeprazole was formulated as EMT uncoated pellets by preparing an aqueous coating solution and coating onto sugar spheres (lacking enteric coating). The aqueous solution was formed by adding polysorbate 80 (Tween® 80, Croda) to water (approximately 5 times the weight of hydroxypropyl methyl cellulose, HPMC) under gentle stirring (330 rpm) until complete dissolution. The resulting solution was then heated at 80° C. HPMC powder (HPMC 2010, PHARMACOAT® 606, Shin-Etsu) was then added in several steps, under stirring at 330 rpm, to promote the dispersion of the particles, as HPMC is insoluble in hot water. Heating was stopped once a homogeneous dispersion was achieved. The remaining cold water volume was then abruptly added, and the resulting solution allowed to cool down at ambient temperature under stirring (stirring speed adjusted to prevent bubble formation).
  • The EMT aqueous suspension of HPMC/polysorbate 80/EMT/water was prepared in a ratio of approximately 10.5/1/44.5/160. EMT powder blend was added in several steps to the HPMC/polysorbate 80/water solution under vigorous stirring (1200 rpm).
  • The EMT aqueous suspension was coated onto inert beads (sugar spheres, grade 850-1000 micrometers, JRS Pharma). Inert beads were pre-heated for 10 minutes (inlet air=53° C.) in a fluid-bed coater (GPCG-1, Glatt) equipped with a Wurster bottom-spray system. The aqueous EMT suspension was then sprayed onto the inert beads (atomizing pressure 1.5 bar) and the layered beads were then subjected to a heating phase (10 min/53° C.) and finally dried under air flow (same flow rate, but without heating) until 30° C. was reached (EMT uncoated pellets).
  • The weight gain of the resulting EMT uncoated pellets at 20 mg esomeprazole dose was approximately 39.1%, with a 130-140 micrometer thickness of EMT coating after drying and a size D10=1100.3 μm/D50=1154.0 μm/D90=1219.2 μm. The final composition of the uncoated pellets for a 20 mg esomeprazole dose per capsules is EMT 21.56% (w/w), 22.3 mg; HPMC 5.09% (w/w), 5.25 mg; polysorbate 80 0.48% (w/w), 0.5 mg; and sugar spheres, 72.87% (w/w), 75.2 mg.
  • The 40 mg EMT uncoated pellet monolithic enteric capsules were filled with 206.4 mg of uncoated pellets, and banded as described in Example 1.
  • Example 3 Dissolution Testing
  • Tested capsules prepared according to Examples 1-4 were filled with pure EMT, EMT uncoated pellets, or powder blend EMT equivalent to 20 mg of esomeprazole. Commercial NEXIUM® (Astra Zeneca) products were purchased in a drugstore and were tested as is (dosage=20 mg or 20 mg esomeprazole). The commercial product delayed release capsule is coated pellets within a gelatin capsule, wherein the internal enteric coated pellet formulation has glyceryl monostearate 40-55, hydroxypropylcellulose (HPC), hypromellose (HPMC), magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sugar spheres, talc and triethyl citrate in a gelatin capsule (NEXIUM® patient leaflet, 2012).
  • The commercial product is also available as a tablet (NEXIUM® tablets, “Multiple Unit Pellet System” or MUPS). The tablet's complex composition includes 17 excipients, starting from the same enteric coated pellets in the delayed release capsule form plus microcrystalline cellulose, hard paraffin hard, Macrogol 6000, crospovidone, sodium stearyl fumarate, and colorants (NEXIUM® tablets MUPS, patient leaflet, 2011).
  • The dissolution method was performed according to the USP monograph for Esomeprazole Magnesium Delayed-Release Capsule. Briefly, capsules were tested in apparatus 2 at 100 rpm, with sinker, at 37° C.±0.5° C., wherein the acid stage is 2 hours in 300 mL of 0.1 N HCl medium, followed by the buffer stage which is the addition of 700 mL of 0.086M dibasic sodium phosphate to adjust the pH to 6.8. The requirements under the specifications are during the acid stage no unit more than 10% dissolved after 2 hours in 0.1N HCl medium, and buffer stage no unit less than 80% (Q+5%) dissolved after 30 min at pH 6.8. The measured results were the % EMT dissolved relative to the initial label claim/capsule dosage (20 mg).
  • For comparative purposes, the commercial esomeprazole delayed release capsule (20 mg) showed quick dissolution of the capsules but no dissolution of the pellets in the acid stage (EMT 120 minute mean was 0%, n=6), and complete dissolution of the pellets during the buffer stage where the 30 minute mean for EMT release was 94% (n=6). The commercial enteric tablets product (20 mg) similarly showed no dissolution of the EMT from the tablets in the acid stage (EMT 120 minute mean was 0%, n=6), and the 30 minute mean for EMT release from the tablets during the buffer stage was 94% (n=6).
  • The pure EMT in the monolithic enteric capsule showed no release of EMT in the acid stage and the capsule itself did not dissolve during the acid stage (three trials, 120 minute mean was 0%, n=6 each trial); the dissolution medium remained clear. The buffer stage gave complete disintegration of the capsules; the 30 minute mean for three manufacturing trials provided 49% (n=6), 31% (n=6), and 65% (n=6) EMT release. Therefore, the monolithic enteric capsules showed good enteric release even containing only pure powdered acid sensitive active ingredient, and without any need for enteric coating. This test was designed to represent the theoretical maximum contact of acid sensitive active ingredient with the capsule shell.
  • Example 4
  • The EMT in the EMT powder blend prepared according to Example 2, filled into the monolithic enteric capsule of Example 1, and tested according to the dissolution protocol of Example 3 showed no release of EMT in the acid stage and the capsule itself did not dissolve during the acid stage (two trials, 120 minute mean was 0%, n=6 each trial). The buffer stage gave complete disintegration of the capsules; the 30 minute mean for two manufacturing trials provided 91% (n=6) and 93% (n=6) EMT release. The pharmacopeia specifications for esomeprazole magnesium delayed release capsules were reached. Therefore, the monolithic enteric capsules showed excellent enteric release containing a powdered blend of an acid sensitive active ingredient, and without any need for enteric coating. This dissolution result closely resembled the commercial tablet and capsule product results.
  • Example 5
  • The EMT in the EMT uncoated pellets prepared according to Example 2, filled into the monolithic enteric capsules of Example 1, and tested according to the dissolution protocol of Example 3, showed no release of EMT in the acid stage and the capsule itself did not dissolve during the acid stage (three trials, 120 minute mean was 0%, n=6 each trial), the dissolution medium remained clear. The buffer stage gave complete disintegration of the capsules after 20 minutes; the 30 minute mean for three manufacturing trials provided 97% (n=6), 95% (n=6), and 98% (n=6) EMT release. The pharmacopeia specifications for esomeprazole magnesium delayed release capsules were reached. Therefore, the monolithic enteric capsules showed excellent enteric release containing uncoated pellets of an acid sensitive active ingredient, and without any need for enteric coating. This dissolution result equaled or exceeded the commercial tablet and capsule product results.
  • Example 6 Pharmacoscintigraphy Testing
  • Monolithic enteric capsules were prepared according to Example 2, but sufficient uncoated pellets were added to provide a 40 mg esomeprazole dose. Radiolabelling was provided by adding approximately 4 MBq 99mTc (Technetium-99m, West of Scotland Radionuclide Dispensary, Glasgow) as a radioactive tracer, measured at the time of dosing. A suitable dose of radioactivity (0.3 mSv in total) was chosen to provide a signal of adequate quality while exposing the subjects to the minimum possible radiation. Non-disintegrating pellets labeled with technetium-99m pertechnetate were added into each capsule (both the tested capsules and the commercial product) to allow scintigraphic monitoring. Complexation of 99mTc to an anionic resin within the radiolabelled placebo pellets prevented absorption of the radiopharmaceutical from the GI tract. The tested capsules with 99mTc placebo pellets and EMT uncoated pellets according to Example 6 were banded (see Example 1). The commercial 40 mg esomeprazole capsules (NEXIUM®)(“commercial product”) were opened and the 99mTc placebo pellets were added; these immediate release gelatin capsules are not sealed at manufacture and so were not changed after the addition of the radioactive tracer. The radiolabelled placebo pellets were similar in size, shape, and density to the coated and uncoated pellets containing the active ingredient.
  • Scintigraphy imaging via gamma camera was performed according to standard medical diagnostic testing procedures with anterior and posterior images acquired at initial dosing and at regular time intervals post initial dosing. Specifically, anterior and posterior images of 25 seconds each were acquired at dosing, then every 10 minutes to 2 hours post-dose, then every 15 minutes to 5 hours post-dose, then every 30 min to 12 hours post-dose with the subjects (standing position, Siemens E-Cam gamma camera fitted with a low-energy high-resolution collimator). Pharmacokinetic information was obtained via blood sampling pre-dose and at regular time intervals post initial dosing according to established procedures. The radiolabelled capsules (both Example 6 and commercial capsules) were administered to the indicated number of subjects (Table 2). Subjects were dosed standing up and instructed to swallow the capsule whole with 240 mL room temperature water.
  • Table 1 illustrates the comparative location of release in vivo as determined from the scintigraphic imaging, and confirms enteric release of the monolithic enteric capsules under a fasting state. All of the Example 6 capsules released in either the small intestine or the ileocecal junction, and none released in the stomach. In contrast, all of the commercial capsule product tested in patients released in either the esophagus or the stomach (as expected from use of immediate release gelatin capsules). No capsules failed to release and/or remained in the stomach or small intestine after 12 hours for either tested formulation.
  • TABLE 1
    Esomeprazole
    Commercial
    Example 6 Product
    Site of Release Onset (n = 12) (n = 14)
    Esophagus 0 2
    Stomach 0 12
    Small intestine 11 0
    Ileocecal junction 1 0
  • Table 2 shows the release time profiles for median values given in minutes for the site of release onset under a fasting state as measured by scintigraphic imaging. The monolithic enteric capsules opened only after gastric emptying, but the commercial product, with enteric coated pellets in a gelatin capsule, were released prior to gastric emptying.
  • TABLE 2
    Esomeprazole
    Commercial
    Example 6 Product
    Site of Release Onset (n = 12) (n = 14)
    Gastric emptying of capsule 55 30
    Onset of radiolabelled pellets 90 5
    release
    Completion of radiolabelled 120 30
    pellets release
    From gastric emptying to onset +35 −25
    of pellets release
    From onset to completion of 30 25
    pellets release
  • Example 7 Pharmacokinetic Testing
  • Monolithic enteric capsules containing EMT uncoated pellets (40 mg) prepared as described in Example 6 were selected for in vivo testing in a randomized, open label, three-treatment, three period, three sequence, crossover, single dose pharmacoscintigraphy study in healthy volunteers and compared to the commercial esomeprazole delayed release capsule NEXIUM® product (Astra Zeneca), which has enterically coated pellets. Time points for plasma sampling were pre-dose and 0.5, 0.75, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, 10, and 12 hours post-dose. Patients were selected from volunteers aged 18 to 65 years, inclusive, with a Body Mass Index (BMI) between 18.0 and 29.9 kg/m3 inclusive and free from any significant diseases including cardiac, renal and gastrointestinal disease. Selected patients were randomized to three treatment arms and three treatment sequences-monolithic enteric capsule fasted state, monolithic enteric capsule fed state, and commercial product fasted state. The crossover design eliminated potential treatment effects on the outcome, as well as effectively allowing the subject to serve as his own control. Each dosing occasion was separated by a 7-14 day washout period. Fasting conditions represented an overnight fast of at least 10 hours and fed state was after a high calorie, high fat breakfast 30 minutes prior to dosing.
  • The % EMT was quantified from human plasma according to methods based on the FDA Bioanalytical Method Validation Guide for Industry and the EMA Guideline on bioanalytical method validation (York Bioanalytical Solutions). Briefly, plasma samples were submitted to supported liquid extraction and liquid chromatography with tandem mass spectrometric detection (lower limit of quantification 5.00 ng/ml with a sample aliquot volume of 100 microliters). The analytes detected were esomeprazole, 5-hydroxyomeprazole, and omeprazole sulphone and were validated against commercial samples and calibration standards. Results obtained with 5-hydroxyomeprazole and omeprazole sulphone were similar to esomeprazole (not shown). Calibration samples were obtained commercially as follows: esomeprazole (Sigma-Aldrich), 5-hydroxyomeprazole, and omeprazole sulphone (Toronto Chemicals Inc.). Internal standards omeprazole d3, 5-hydroxyomeprazole d3 and omeprazole sulphone-d3 were also utilized (Toronto Chemicals Inc.). Plasma samples were stored at −20° C. Data was collected using Analyst software (Applied Biosystems-Sciex) in combination with Watson LIMS (Thermo Fisher Scientific); peak area ratios were used to generate calibration curves using regression functions.
  • The in vivo pharmacokinetic results obtained (shown in Tables 3 and 4) illustrate that the monolithic enteric capsule product surprisingly exhibited a statistically significant delay in onset time of quantifiable plasma concentrations as compared to the multiparticulate, enteric coated commercial dosage form of an acid sensitive active ingredient. The monolithic uncoated pellet product prepared according to Example 6 had an average onset time of 108 minutes, considerably longer than the 66 minutes for the commercial product (p=0.0426).
  • Surprisingly, the monolithic enteric capsule product reached the highest plasma level (Cmax) more rapidly than the commercial esomeprazole product, i.e., within an average of 36 minutes as compared to an average of 63 minutes (p=0.0166). This delivery system provides a short intestinal release time period.
  • TABLE 3
    Comparisons of quantifiable plasma concentrations and intestinal release and
    absorption time (fasting)
    Onset time in blood Tmax Difference
    Comm. Comm. (Tmax − Onset)
    Ex. 6 product Ex. 6 product Comm.
    Subj Hrs min Hrs min Hrs min hrs min Ex. 6 Product
    1 0.75 45 0.75 45 1.25 75 1.25 75 30 30
    2 1.02 61.2 0.85 51 1.27 76.2 2.02 121.2 15 70.2
    3 1.52 91.2 1.68 100.8 2.53 151.8 2.27 136.2 60.6 35.4
    4 1.55 93 1.02 61.2 2.03 121.8 2 120 28.8 58.8
    5 1.52 91.2 0.65 39 2.02 121.2 1.52 91.2 30 52.2
    6 0.78 46.8 3.03 181.8 1.27 76.2 5.02 301.2 29.4 119.4
    8 2.02 121.2 0.52 31.2 2.52 151.2 1.5 90 30 58.8
    9 1.52 91.2 0.52 31.2 2.02 121.2 1.25 75 30 43.8
    10 0.52 31.2 0.75 45 1.02 61.2 2.53 151.8 30 106.8
    11 3.97 238.2 0.8 48 5.58 334.8 1.02 61.2 96.6 13.2
    12 2.52 151.2 1.02 61.2 2.52 151.2 2.02 121.2 0 60
    15 2.53 151.8 1.02 61.2 3.03 181.8 1.52 91.2 30 30
    16 1.53 91.8 1.53 91.8 2.02 121.2 2.52 151.2 29.4 59.4
    17 3.53 211.8 1.23 73.8 4.53 271.8 3.53 211.8 60 138
    mean 1.81* 108.3* 1.10* 65.87* 2.40 144.04 2.14 128.4 35.7** 62.57**
    SD 1.02 61.2 0.65 39.2 1.28 77.0 1.06 63.6 23.1 35.9
    Median 1.525 91.5 0.935 56.1 2.025 121.5 2.01 120.6 30 58.8
    Note:
    Statistical significance between Example 6 and esomeprazole commercial product
    *p = 0.0426 in Kruskal-Wallis Test;
    **p = 0.0166 in Kruskal-Wallis Test
  • TABLE 4
    Comparison of the rate of absorption: Cmax/(Tmax − Tlag) (fasting)
    Ex. 6 (Enteric capsule filled with Commercial Product (capsule filled with
    uncoated pellets) enteric coated pellets)
    Tmax Cmax/(Tmax Tmax Cmax/(Tmax
    Tlag Tmax Cmax Tlag Tlag) Tlag Tmax Cmax Tlag Tlag)
    Subj (hr) (hr) (ng/mL) (hr) (ng/mL/hr) (hr) (hr) (ng/mL) (hr) (ng/mL/hr)
    1 0.52 1.25 1770.00 0.73 2424.66 0.52 1.25 1610.00 0.73 2205.48
    2 0.77 1.27 1430.00 0.50 2860.00 0.53 2.02 786.00 1.49 527.52
    3 1.25 2.53 2380.00 1.28 1859.38 1.23 2.27 2170.00 1.04 2086.54
    4 1.25 2.03 1020.00 0.78 1307.69 0.73 2.00 457.00 1.27 359.84
    5 1.25 2.02 1260.00 0.77 1636.36 0.00 1.52 874.00 1.52 575.00
    6 0.53 1.27 1980.00 0.74 2675.68 2.53 5.02 1030.00 2.49 413.65
    8 1.52 2.52 1420.00 1.00 1420.00 0.00 1.50 979.00 1.50 652.67
    9 1.27 2.02 1280.00 0.75 1706.67 0.00 1.25 981.00 1.25 784.80
    10 0.00 1.02 801.00 1.02 785.29 0.52 2.53 559.00 2.01 278.11
    11 3.52 5.58 129.00 2.06 62.62 0.52 1.02 1830.00 0.50 3660.00
    12 2.03 2.52 1450.00 0.49 2959.18 0.75 2.02 439.00 1.27 345.6
    15 2.03 3.03 1140.00 1.00 1140.00 0.77 1.52 847.00 0.75 1129.33
    16 1.18 2.02 1860.00 0.84 2214.29 1.27 2.52 1240.00 1.25 992.00
    17 3.02 4.53 1430.00 1.51 947.02 1.02 3.53 1340.00 2.51 533.86
    Mean 1.44 2.40 1382.14 0.96 1714.20* 0.74 2.14 1081.57 1.40 1038.89*
    SD 0.96 1.28 545.31 0.42 847.17 0.66 1.06 511.47 0.60 968.59
    Median 1.25 2.03 1425.00 0.81 1671.52 0.63 2.01 980 1.27 613.84
  • Statistical significance was obtained between Example 6 and the commercial esomeprazole product * with a p value=0.0191 according to the Kruskal-Wallis test. Tlag is the time prior to the first measurable (non-zero) concentration. The results shown in Table 4 illustrate the faster absorption rate of the uncoated pellets in the enteric capsule compared to the enteric coated beads of the commercial product.
  • The formula Cmax/(Tmax−Tlag) is used to measure the rate of absorption (where Tlag equals the measured time prior to the first non-zero drug concentration). Delayed release products are characterized by the fact the drug release is internally delayed. Because of the designed delay, Tmax alone would have limited meaning as a rate of absorption characteristic, and Tmax−Tlag would provide a more meaningful metric. In contrast to Tmax, Cmax may not be affected by the delayed release.
  • Esomeprazole in uncoated pellets in a monolithic enteric capsule prepared according to Example 6 showed a significant difference in vivo between Cmax/(Tmax−Tlag) compared to the commercial product of enteric coated pellets in a gelatin capsule (P value<0.05), based upon actual hours post-dose and individual time points. The mean and standard deviation (SD) of Cmax/(Tmax−Tlag) for uncoated pellets in the monolithic enteric capsule according to Example 6 was 1714 (SD=847) and for the commercial capsule product was 1038 (SD=968), which shows that a much faster absorption rate was achieved in patients treated with the monolithic enteric capsules of Example 6.
  • The ratio of Example 6 monolithic enteric capsules compared to the commercial product showed an increase in Cmax of 56% in in vivo testing, with a ratio of 155.75% (90% confidence interval 86.93, 279.07, geometric least squares means). The ratio of the Example 6 monolithic enteric capsules compared to the commercial product showed an increase in AUC of 132% in in vivo testing, with a ratio of 131.67% (90% confidence upper interval 220.96, geometric least squares means). Despite these increases in bioavailability, the rate of drug elimination was similar after release into the gastrointestinal tract, i.e., Example 6 vs. commercial product was Kei (1/h) 0.593 (±0.149) vs. 0.60 (±0.203).
  • The fed samples provided a delayed release beyond the test period. Food effect delay is known from the commercial product, which is designated to be taken at least one hour before meals. The high fat meal did not affect the integrity of the Example 6 capsules within the stomach.
  • Table 5 provides the means and standard deviation for the pharmacokinetic parameters for the Example 6 samples, fed and fasted, compared to the commercial product (enteric coated pellets in a capsule).
  • TABLE 5
    Mean ± SD
    Commercial
    Ex. 6, Ex. 6 Product
    PK (fasting) (fed) (fasting)
    Parameter (Unit) N = 14 N = 14 N = 14
    Cmax (ng/mL) 1382 (±545) 256 (±328) 1082 (±511)
    Tmax (h)* 2.40 (±1.3) 10.8 (±2.25) 2.14 (±1.1)
    (Median = (Median = (Median =
    2.03) 11.63) 2.01)
    AUC0-t (ng · h/mL) 2819 (±2003) 264 (±316) 2692 (±2079)
    AUC0-∞ (ng · h/mL) 2876 (±2113) 2770 (±2268)
    Kel (1/h) 0.6 (±0.15) 0.6 (±0.20)
    t1/2 (h) 1.3 (±00.4) 1.4 (±0.8)
    (Ln-transformed) Geometric LS Means
    Cmax (ng/mL) 1544.72 991.78
    AUC0-t (ng · h/mL) 2949.94 2240.46
    AUC0-∞ (ng · h/mL) 2448.71 2254.23
    Ratio (%): Ex. 6 vs Commercial Product
    Cmax (ng/mL) 155.75
    AUC0-t (ng · h/mL) 131.67
    AUC0-∞ (ng · h/mL) 108.63
  • Table 6 shows the variability of the pharmacokinetic parameters obtained according to Examples 6 and 7.
  • TABLE 6
    Type of Variability/ Coefficient of Variation
    PK Parameters (CV %)
    Intra-subject Esomeprazole
    AUCinf 40.85
    AUCt 83.08
    Cmax 97.51
    Example 6 Comm. Prod.
    Inter-subject (Fasting) (Fasting)
    AUCinf 73.43 81.89
    AUCt 71.07 77.24
    Cmax 39.45 47.29
    Tmax 53.5 49.5
    t1/2 33.1 56.21
  • Example 8
  • Active ingredients imatinib mesylate, mesalamine, mycophenate sodium, ibuprofen, insulin, desmopressin, and somatropin will be tested according to the preceding Examples to illustrate the monolithic enteric capsule systems and methods.
  • Other embodiments of the present disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the present disclosure. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the present disclosure being indicated by the following claims.

Claims (16)

1. An enteric drug delivery system comprising: a monolithic enteric hard capsule filled with the active pharmaceutical ingredient, wherein the active pharmaceutical ingredient has not been enterically coated for modified release or gastric protection, wherein less than about 10% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 2 hours in a pH of about 1.2, wherein at least about 80% of the active pharmaceutical ingredient is released from the monolithic enteric capsule after about 30 min at pH of about 6.8, and wherein more than about 95% of the active ingredient is released in the intestine; wherein the active pharmaceutical ingredient is a proton pump inhibitor selected from the group consisting of dexlanzoprazole, esomeprazole, ilaprazole, leminoprazole, lanzoprazole, omeprazole, pantoprazole, paripiprazole, rabeprazole, tenatoprazole and combinations, pharmaceutically acceptable salts, derivatives, and enantiomers thereof.
2. The system according to claim 1, wherein the monolithic enteric capsule yields a peak plasma concentration (Cmax) that is equal to or higher than the peak plasma concentration achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where Cmax is increased by up to about 279%.
3. The system according to claim 1, wherein the monolithic enteric capsule yields an Area Under Curve (AUC0-t) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC0-t achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC0-t is increased up to about 220%.
4. The system according to claim 1, wherein the monolithic enteric capsule yields an Area Under Curve (AUC0-∞) plasma concentration of the active pharmaceutical ingredient equal to or higher than the AUC0-∞ achieved by the active pharmaceutical ingredient from administration of an oral dosage form comprising at least one enteric coating for modified release or gastric protection, particularly where AUC0-∞ is increased up to about 162%.
5. The system according to claim 1, wherein the monolithic enteric capsule has an increase in oral bioavailability from about 10% to about 50% on average compared to bioavailability of the active pharmaceutical ingredient in an oral dosage form comprising at least one enteric coating for modified release or gastric protection.
6. The system according to claim 1, wherein the active pharmaceutical ingredient is esomeprazole or its pharmaceutically acceptable salts.
7. A method of increasing bioavailability of an active pharmaceutical ingredient (API), comprising administering to a human in need thereof a therapeutically effective amount of at least one API in a monolithic enteric hard capsule, wherein said API has not been coated for modified release or gastric protection, wherein the bioavailability of said API is increased compared to API having an enteric coating for modified release or gastric protection.
8. The method according to claim 7, wherein the API is acid labile or has gastric side effects.
9-10. (canceled)
11. A monolithic enteric capsule, comprising:
a non-salified functional polymer, said polymer being present in an amount ranging from about 50% to about 75% by weight of the total weight of the empty capsule;
at least one processing aid present in an amount ranging from about 10.5% to about 20% by weight of the total weight of the empty capsule; and
water present in an amount ranging from about 1% to about 20% by weight over the total weight of the empty capsule.
12. The monolithic enteric capsule according to claim 11, wherein the monolithic enteric capsule provides an increased rate of absorption Cmax/(Tmax−Tlag) for the active pharmaceutical ingredient after administration to a patient as compared to the rate of absorption of the active pharmaceutical ingredient having an enteric coating for modified release or gastric protection from about 30 ng/mL/hr to about 3400 ng/mL/hr.
13. The monolithic enteric capsule according to claim 11, wherein the monolithic enteric capsule decreases the time to achieve peak plasma concentration (Tmax−Tlag) for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in pellets or tablets, preferably decreasing by from about 0.1 hour to about 2.0 hours.
14. The monolithic enteric capsule according to claim 11, wherein the monolithic enteric capsule decreases the time to achieve peak plasma concentration for the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in solid dosage forms selected from the group consisting of beads, caplets, capsules, granules, microparticles, multiparticulates, microspheres; powders, pellets, solid lipid pellets, tablets, and combinations thereof, preferably decreasing by from about 10 minutes to about 90 minutes.
15. The monolithic enteric capsule according to claim 11, wherein the monolithic enteric capsule provides an increased lag time after administration to a patient for release of the active pharmaceutical ingredient compared to the active pharmaceutical ingredient coated for modified release or gastric protection in solid dosage forms selected from the group consisting of beads, caplets, capsules, granules, microparticles, multiparticulates, microspheres; powders, pellets, solid lipid pellets, tablets, and combinations thereof, preferably where the increase in lag time is from about 0.1 hour to about 4.3 hours.
16. The monolithic enteric capsule according to claim 11, wherein the monolithic enteric capsule lacks internal excipients.
17. An oral pharmaceutical dosage form, comprising the monolithic enteric hard capsule of claim 11, wherein the monolithic enteric hard capsule is filled with at least one proton pump inhibitor free of enteric coating, wherein the monolithic enteric hard capsule yields a peak plasma concentration higher than the peak plasma concentration achieved by the proton pump inhibitor having an enteric coating for modified release or gastric protection.
US15/030,302 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole Abandoned US20160256399A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/030,302 US20160256399A1 (en) 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899586P 2013-11-04 2013-11-04
US15/030,302 US20160256399A1 (en) 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
PCT/US2014/062210 WO2015065848A1 (en) 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/062210 A-371-Of-International WO2015065848A1 (en) 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/151,253 Continuation US10813886B2 (en) 2013-11-04 2018-10-03 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Publications (1)

Publication Number Publication Date
US20160256399A1 true US20160256399A1 (en) 2016-09-08

Family

ID=51947475

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/030,302 Abandoned US20160256399A1 (en) 2013-11-04 2014-10-24 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
US16/151,253 Expired - Fee Related US10813886B2 (en) 2013-11-04 2018-10-03 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/151,253 Expired - Fee Related US10813886B2 (en) 2013-11-04 2018-10-03 Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole

Country Status (3)

Country Link
US (2) US20160256399A1 (en)
EP (1) EP3065720A1 (en)
WO (1) WO2015065848A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076920A1 (en) 2019-10-16 2021-04-22 Capsugel Belgium Nv Method and composition for increasing muscle protein synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805737A (en) * 2012-09-03 2012-12-05 海南中化联合制药工业股份有限公司 Lansoprazole enteric oral disintegrating tablet and preparation method thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643853A (en) 1946-04-13 1950-09-27 Lilly Co Eli Medicinal capsules and process of manufacture
GB672814A (en) 1949-11-25 1952-05-28 Parke Davis & Co Process and apparatus for manufacturing capsules
US2718667A (en) 1952-05-01 1955-09-27 Eastman Kodak Co Method of preparing enteric capsules
GB1144225A (en) 1965-09-07 1969-03-05 Dow Chemical Co Preparation of medicinal capsule shells from hydroxyalkyl-alkyl cellulose ethers
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3617588A (en) 1969-06-16 1971-11-02 Dow Chemical Co Dip-coating process for preparing cellulose ether capsule shells
CA944689A (en) 1970-07-28 1974-04-02 Claude Rene Capsules en matieres plastiques et leurs procedes de fabrication
US4001211A (en) 1974-12-02 1977-01-04 The Dow Chemical Company Pharmaceutical capsules from improved thermogelling methyl cellulose ethers
US4138013A (en) 1976-08-27 1979-02-06 Parke, Davis & Company Enteric capsules
WO1980000659A1 (en) 1978-10-02 1980-04-17 Purdue Research Foundation Food and pharmaceutical coating composition,method of preparation and products so coated
EP0056825B1 (en) 1981-01-22 1984-12-05 Capsugel A.G. A process for producing a pharmaceutical capsule having enteric properties
JPS58138458A (en) 1982-02-10 1983-08-17 信越化学工業株式会社 Preparation of capsul dissolved in intestine
DE3222476A1 (en) 1982-06-15 1983-12-15 Warner-Lambert Co., 07950 Morris Plains, N.J. Soft gelatin capsules resistant to gastric fluid, and process for the production thereof
US4656066A (en) 1982-12-20 1987-04-07 Warner-Lambert Company Apparatus and method for sealing capsules
US4539060A (en) 1983-02-18 1985-09-03 Warner-Lambert Company Apparatus and method of sealing capsules
JPS62104593A (en) 1985-10-31 1987-05-15 Terumo Corp Culture medium composition for testing amino acid decarboxylation ability
EP0352800A3 (en) 1988-07-28 1991-05-08 Warner-Lambert Company Aqueous polymeric dispersion of cellulosic and acrylic based polymers for preparing pharmaceutical dosage forms and dosage forms thereof
JPH0634807B2 (en) 1989-06-08 1994-05-11 信越化学工業株式会社 Method for manufacturing hard capsules for medicine
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
JP2552937B2 (en) 1990-03-29 1996-11-13 日本エランコ株式会社 Pharmaceutical hard capsule and method for producing the same
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
ES2174849T3 (en) 1992-06-04 2002-11-16 Smithkline Beecham Corp PHARMACEUTICAL COMPOSITIONS WITH NICE FLAVOR.
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
JP3017906B2 (en) 1993-10-08 2000-03-13 信越化学工業株式会社 Enteric coating agent dispersion
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP5068401B2 (en) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Intestinal and colonic delivery using HPMC capsules
FR2787729B1 (en) 1998-12-29 2001-01-26 Oreal NANOCAPSULES BASED ON HYDRODISPERSIBLE ANIONIC POLYMERS, THEIR PREPARATION METHOD AND COSMETIC OR DERMATOLOGICAL COMPOSITIONS CONTAINING THEM
DE19901686A1 (en) 1999-01-18 2000-07-20 Gruenenthal Gmbh Retarded tramadol preparations with a storage-stable release profile and process for their preparation
WO2001023000A1 (en) 1999-09-30 2001-04-05 Otsuka Pharmaceutical Company, Limited Coating preparations soluble in lower digestive tract
EP1184033A1 (en) 2000-09-01 2002-03-06 Warner-Lambert Company Pectin film compositions
SE0100200D0 (en) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
EP1262174A1 (en) 2001-06-01 2002-12-04 Celanese Ventures GmbH Two part hard shell capsule made of poly(1,4-alpha-D-glucane) and starch
KR100461566B1 (en) 2001-11-15 2004-12-14 삼성정밀화학 주식회사 Preparation method of solvent-free water dispersible hydroxypropyl methyl cellulose phthalate nanoparticle
ATE487472T1 (en) 2001-11-22 2010-11-15 Morishita Jintan Co NON-GELATINAOUS CAPSULES
FR2829142B1 (en) 2001-12-27 2004-02-13 Ulice FILMOGENEOUS COMPOSITION OF HETEROXYLANE FOR THE MANUFACTURE OF CAPSULES THUS OBTAINED
US20030161872A1 (en) 2002-01-04 2003-08-28 Gan-Lin Chen Capsule for holding liquid-containing compositions and method for making the same
WO2004012701A2 (en) 2002-08-02 2004-02-12 Scitech Centre NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS.
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
ES2500316T3 (en) 2002-10-01 2014-09-30 Banner Pharmacaps, Inc. Enteric composition for the manufacture of a soft capsule shell
EP1459725B1 (en) 2003-03-21 2007-10-17 Warner-Lambert Company LLC Apparatus for and method of sealing capsules
EP1663173A1 (en) * 2003-09-25 2006-06-07 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
TW200520790A (en) 2003-12-22 2005-07-01 Dah Feng Capsule Industry Co Ltd The compositions of a vegetarian capsule shell
AR048033A1 (en) 2004-03-12 2006-03-22 Smithkline Beecham Plc PHARMACEUTICAL COMPOSITION TO MOLD COMPONENTS THAT INCLUDE COPOLIMERO OF POLY (MET) ACRYLATE, COVER, CONNECTOR OR SPACER OF CAPSULA MOLDED BY INJECTION THAT HAS THE PHARMACEUTICAL COMPOSITION AND FORM OF PHARMACEUTICAL MULTI-COMPONENT COMPONENTS
WO2005113010A1 (en) 2004-05-24 2005-12-01 Qualicaps Co., Ltd. Surface-modified and solubility-improved hard capsule
JP2006016372A (en) * 2004-07-05 2006-01-19 Shionogi Qualicaps Co Ltd Enteric hard capsule
WO2006082842A1 (en) 2005-02-03 2006-08-10 Qualicaps Co., Ltd. Hard capsule having improved solubility
WO2006132398A1 (en) 2005-06-06 2006-12-14 Ajinomoto Co., Inc. Capsule coating composition
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20070053869A1 (en) 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
CN101400343B (en) 2006-03-16 2012-01-11 特瑞斯制药股份有限公司 Modified release formulations containing drug-ion exchange resin complexes
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
CA2597740C (en) 2006-04-26 2012-10-16 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
KR101123525B1 (en) 2006-10-24 2012-03-13 화이자 프로덕츠 인코포레이티드 Combination of conveying line and processing station
ES2744816T3 (en) 2006-10-27 2020-02-26 Capsugel Belgium Nv Hydroxypropyl methyl cellulose hard capsules and manufacturing process
GB0706178D0 (en) 2007-03-29 2007-05-09 Univ Aston Enteric pharmaceutical capsules
JP5379121B2 (en) 2007-04-05 2013-12-25 ユニバーシティ・オブ・カンザス Fast dissolving pharmaceutical composition comprising pullulan
CN101778870B (en) 2007-08-02 2012-11-07 巴斯夫欧洲公司 Aqueous polymer dispersion based on n,n-diethylaminoethyl methacrylate, its preparation and use
US20090074944A1 (en) 2007-09-18 2009-03-19 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
EP2211820B1 (en) 2007-10-19 2012-05-02 Capsugel Belgium NV Multi-compartmented container
US8268356B2 (en) 2007-11-16 2012-09-18 Asahi Kasei Chemicals Corporation Aqueous film coating solution, film coated granule and tablet using the same
WO2010080449A1 (en) 2008-12-18 2010-07-15 Adds Pharmaceuticals Llc Blow-molded thin-walled drug delivery capsules
US9107451B2 (en) 2009-07-29 2015-08-18 Evonik Röhm Gmbh Coating composition for the dip coating of capsule halves
KR101705204B1 (en) * 2009-09-11 2017-02-09 롯데정밀화학 주식회사 Aqueous composition for hard capsule having enteric properties, method of preparing hard capsule having enteric properties and hard capsule prepared by the latter
US8852631B2 (en) 2009-09-24 2014-10-07 Capsugel Belgium Nv Acid resistant capsules
KR101182827B1 (en) 2010-06-11 2012-09-14 삼성정밀화학 주식회사 Method of preparing hard capsule having enteric properties and hard capsule having enteric properties prepared thereby
KR101787481B1 (en) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 Composition for enteric hard capsule and enteric hard capsule prepared by using the composition
EP3354335A1 (en) 2010-10-26 2018-08-01 Capsugel Belgium NV Bulk enteric capsule shells
JP6219836B2 (en) 2011-11-09 2017-10-25 キャプシュゲル・ベルジウム・エヌ・ヴィ Acid-resistant banding solution for acid-resistant two-piece hard capsules
CA2870033C (en) * 2012-05-02 2017-04-18 Capsugel France SAS Aqueous dispersions of controlled release polymers and shells and capsules thereof
EP3145498B1 (en) 2014-05-20 2020-03-04 Dow Global Technologies LLC Dispersion comprising a partially neutralized esterified cellulose ether
TWI587880B (en) 2015-03-24 2017-06-21 Can be made into the composition of enteric capsule shell, enteric capsule shell and its process
US9452141B1 (en) 2015-05-01 2016-09-27 Dah Feng Capsule Industry Co., Ltd. Acid resistant capsule shell composition, acid resistant capsule shell and its preparing process
US20170157058A1 (en) 2015-12-08 2017-06-08 Dah Feng Capsule Industry Co., Ltd. Acid resistant capsule shell composition, acid resistant capsule shell and its preparing process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805737A (en) * 2012-09-03 2012-12-05 海南中化联合制药工业股份有限公司 Lansoprazole enteric oral disintegrating tablet and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021076920A1 (en) 2019-10-16 2021-04-22 Capsugel Belgium Nv Method and composition for increasing muscle protein synthesis

Also Published As

Publication number Publication date
US20190029965A1 (en) 2019-01-31
EP3065720A1 (en) 2016-09-14
WO2015065848A1 (en) 2015-05-07
US10813886B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
Maroni et al. Oral pulsatile drug delivery systems
JP5634882B2 (en) Drug delivery system comprising weakly basic drug and organic acid
ES2221188T3 (en) PHARMACEUTICAL COMPRESSED CONTAINING DIDANOSINE WITH ENTERIC COATING.
JP2020059755A (en) Timed pulsatile release system
KR101489401B1 (en) Drug Delivery Systems Containing Weakly Basic Drugs and Organic Acids
EP2276472B1 (en) Compositions comprising weakly basic drugs and controlled-release dosage forms
JP6150896B2 (en) Gastric juice-resistant pharmaceutical composition or nutritional supplement composition resistant to the effects of ethanol
KR20080098627A (en) Drug delivery system comprising a weakly basic selective serotonin 5-HTH3 blocker and an organic acid
CN109310642B (en) Oral pharmaceutical composition of mesalamine
US20170119680A1 (en) Extended release film-coated capsules
JP2967492B2 (en) Intestinal in-place release oral formulation
RU2738114C2 (en) Oral pharmaceutical compositions of nicotinamide
US20130122090A1 (en) Multiple Unit Tablet Composition
US10813886B2 (en) Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
EP3746091A1 (en) Cholestyramine formulations and methods of use
WO2020101586A1 (en) Controlled release propiverine formulations
US20120321702A1 (en) Pharmaceutical composition of lansoprazole
Šalandová et al. The effect of the composition of a fixed dose combination on bioequivalence results
WO2010018593A2 (en) Gastric acid resistant benzimidazole multiple unit tablet composition
EP0978275A1 (en) Solid pharmaceutical dosage form with controlled drug release
Naiserová et al. perorálních tablet
HK40005191A (en) Oral pharmaceutical compositions of nicotinamide

Legal Events

Date Code Title Description
AS Assignment

Owner name: CAPSUGEL FRANCE SAS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BENAMEUR, HASSAN;REEL/FRAME:039130/0966

Effective date: 20131126

Owner name: CAPSUGEL BELGIUM NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CAPSUGEL FRANCE SAS;REEL/FRAME:039131/0060

Effective date: 20131126

Owner name: CAPSUGEL BELGIUM NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEE, CHANG;REEL/FRAME:039130/0893

Effective date: 20131120

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION